PHARMACEUTICAL OUTCOMES RESEARCH & POLICY …...May 11, 2015 · 2 pharmaceutical outcomes research...

UNIVERSITY OF WASHINGTON SCHOOL OF PHARMACY 1ANNUAL REPORT FALL 2015

PHARMACEUTICAL OUTCOMES RESEARCH & POLICY PROGRAM PORPP

ANNUAL REPORT FALL 2015

20YEARS

CELEBRATING

1995-2015

2 PHARMACEUTICAL OUTCOMES RESEARCH & POLICY PROGRAM PORPP

1 FROM THE DIRECTOR

2 DEDICATION

Our Past4 PORPP – THE FOUNDING

9 PAST ALUMNI – WHERE THEY ARE NOW

Our Present

14 MISSION

15 JUNIOR FACULTY RYAN HANSEN, PHARMD, PHD

16 ACADEMIC PROGRAMS16 PHD, PHARMD/MS & FELLOWSHIPS17 CERTIFICATE IN HEALTH ECONOMICS & OUTCOMES RESEARCH 18 CERTIFICATE IN COMPARATIVE-EFFECTIVENESS19 BIOMEDICAL REGULATORY AFFAIRS PROGRAM

20 RESEARCH HIGHLIGHTS20 PACIFIC NORTHWEST EVIDENCE-BASED PRACTICE CENTER22 RESEARCH PRIORITIZATION: INVESTING WISELY IN HEALTHCARE TECHNOLOGY RESEARCH24 THE 2ND PANEL ON COST-EFFECTIVENESS IN HEALTH & MEDICINE

25 ACADEMIC PARTNERSHIPS25 CAB STRATEGIC PARTNERSHIP 26 CHASE ALLIANCE

27 CURRENT GRADUATE STUDENTS & FELLOWS27 OUR STUDENTS & FELLOWS33 PORPP PRIZE34 ISPOR STUDENT CHAPTER35 ADVANCED METHODS

36 GRADUATE TRAINING36 AHRQ T3237 AHRQ PCOR K12

38 PAST YEAR ACHIEVEMENTS38 AWARDS39 SERVICE 40 STUDENT PUBLICATIONS & PRESENTATIONS42 FACULTY PUBLICATIONS 46 FACULTY GRANTS

47 GIFTS

Our Future

50 RECENT GRADUATES51 INCOMING STUDENTS

53 FACULTY & STAFF

54 ADMINISTRATION

Table of Contents

UNIVERSITY OF WASHINGTON SCHOOL OF PHARMACY 1

It gives me immense pleasure to write to you as the incoming

Director of the University of Washington Pharmaceutical

Outcomes Research and Policy Program and provide you, on

behalf of the program, its annual report. This annual report

also marks the beginning of the twentieth-year anniversary

of the program. To commemorate this occasion, we have

developed this report to celebrate the program’s past, to

cherish its present, and to think big for its future. As you will

see in reviewing this, PORPP continues to grow in number

and in the achievements of its talented and dedicated staff

working collaboratively across a wide range of disciplines.

However, this success is built on the shoulders of its founding

members, alumni and our corporate advisors whose

continued support is instrumental to our success in the

future. It is providence that two of our founding members,

Andy Stergachis and Sean Sullivan are now steering the

Dean’s office in the School of Pharmacy.

This past year has been an exceptionally strong year of

achievements for our program. Professor Lou Garrison was

elected to be the incoming President of ISPOR. In the 2015

ISPOR Annual meeting, Research Assistant Professor Aasthaa

Bansal won the best podium by a new investigator, PhD

student Kai Yeung won the best podium by student, post-doc

Julia Slejko won the best poster by a new investigator, and

alumnus Chris Wallick won the best poster award. Alumnus

Joshua Roth received the ISPOR Applied Paper of the year

award and, more recently, the Award for Outstanding Paper

by a Young Investigator from the Society for Medical Decision

Making. Aasthaa Bansal received the PhRMA 2015 new

investigator fellowship while PhD student William Canestaro

received the PhRMA 2015 pre-doctoral fellowship. Research

assistant professor Ryan Hansen led-work linking use of

sleeping pills and motor vehicle crashes which drew national

and international attention. Finally, in a historic move, and

based on decades of work by the School of Pharmacy faculty,

especially Professor Don Downing, Washington will be the

first state in the country to require that pharmacists are

included in health insurance provider networks under new

legislation (SB 5557) signed by Governor Inslee on Monday,

May 11, 2015. This creates tremendous opportunity for

PORPP faculty to engage in many facets of policy designs and

evaluations.

Our training programs are going strong. For this coming

year, we are admitting another strong new graduate program

cohort. Professors Hazlet, Devine, Garrison, Carlson, and

Veenstra recruited our top candidates, who are profiled here.

Our Distance Learning Certificate in Health Economics and

Outcomes Research will welcome another large batch of

students this fall. We have now trained nearly 200 students

through this mechanism.

I would like to thank Professor Lou Garrison for serving as the

Interim Director for the program this past year and making

my transition as smooth as possible. I would also thank all

of our past and present Corporate Advisory Board members

for their continued support to the program. The Outcomes

CAB will also celebrate its fifteenth anniversary this year and

a profile on its history with PORPP is provided in this report.

Finally, I want to thank Penny Evans and Paul Kraegel, our

superb program and research coordinators, who help to

make all of this possible. This also marks Penny’s twentieth

year of service to PORPP and a full profile of her contributions

to the program is highlighted here. This 20th anniversary

report is dedicated to her.

FROM THE DIRECTOR

1

Anirban Basu, PhD, Professor, Stergachis Family Endowed Director, PORPP, Adjunct Professor, Health Services


OUR PASTPORPP has been extremely fortunate to have Penny Evans

work with PORPP faculty, students and staff throughout its

entire 20-year history. Starting as a Program Coordinator in

1995, she helped with the initial database for the mailing of

the then quarterly “PORPP Report”. As the Graduate Program

Advisor and Program Operations Specialist for the past 13

years, she has been the heart and soul of the program. She

has coached and encouraged all of our graduate students.

And she has always served as the warm and friendly face of

the program to outsiders.

Penny’s list of contributions is endless: organizing recruiting

activities for new students, mentoring current students in

fulfilling course and dissertation requirements, attending

and assisting with our weekly graduate seminar, handling

the PORPP financial accounts, assisting students to organize

general exam and dissertation defenses, coordinating and

administering our prelim exams, representing PORPP in

departmental administrative coordination, and so on.

Penny is the ultimate team player: doing whatever she can

to help both PORPP and the Department. Dean Sullivan

has called her: “the perfect employee-assistant: whenever

there is a PORPP or school event, Penny is either planning it,

coordinating it, or helping make it successful.” She focuses

on the positive in her colleagues and students, and helps to

bring out the best in all of us.

DEDICATION: PENNY L. EVANS

This past year, the Department of Pharmacy nominated

Penny for the prestigious University of Washington

Distinguished Staff Award. Here is an excerpt from one of the

nomination letters:

“…She has supported every program graduate and faculty

member since the program was founded in 1995, and her

touch is noted by all as critical to the program’s success…”

Even though she was not one of the five winners out of 60

nominees, we all consider her a “winner” in her own right.

Penny is a keeper of the history of PORPP, having contributed

to much of it and documenting what has occurred in words

and photos. We dedicate this 20th Anniversary Report to her,

with deep gratitude for what she has done to make PORPP

what it is today.


OUR PAST Our Past4 PORPP – THE FOUNDING

9 PAST ALUMNI – WHERE THEY ARE NOW


PORPP: THE FOUNDING

“Great scientists and great surfers share a common trait. They don’t position

themselves where the big wave is now; they position themselves where the next

big wave is going to be. PORPP teaches students to read the patterns in scientific

methods, to understand the history that built up behind the last big waves, and

to prepare for the ride of your life when you finally catch the big one.”

MITCH HIGASHI, `01, GE HEALTHCARE’S CHIEF ECONOMIST


A BLUEPRINT FOR PROGR AM DEVELOPMENT


The Pharmaceutical Outcomes Research and Policy Program

(PORPP) began largely out of a response to student and

workforce needs. In 1989, Andy Stergachis, the current

Associate Dean for Research, Graduate Programs and

New Initiatives, was recruited from Group Health’s Center

for Health Studies by Dean Milo Gibaldi to join the then-

Department of Pharmacy Practice. Stergachis was advising

David H. Smith, a student looking to begin a Ph.D., when he

had a “lightbulb” moment that ultimately led to the founding

of PORPP.

Smith knew he wanted to do his doctorate work in Pharmacy,

but UW did not offer a Ph.D. in Pharmacy. In the end,

Smith chose an unconventional route and created his own

interdisciplinary graduate program of study. As the School’s

first Ph.D. graduate in pharmacy outcomes research,

Smith went on and has achieved national prominence as

Senior Investigator at Kaiser Permanente Center for Health

Research.

What stayed with Stergachis was the need for a formal

Ph.D. program in Pharmacy. Gibaldi, who had long wanted

a doctoral program in Pharmacy, was very supportive. And

with that, Stergachis and others began to develop a plan.

In 1990, Stergachis was awarded the Burroughs Wellcome/

American College of Preventive Medicine Scholar in

Pharmacoepidemiology Award, a 5-year career development

award. The funding from that award provided much-

needed seed funding for salaries, curriculum development,

and support for new visiting faculty and fellows to the

burgeoning program, including epidemiologist Dr. Jackie

Gardner and a newly-minted Ph.D. from UC Berkeley named

Sean D. Sullivan.

Sullivan and Stergachis first met at an APhA meeting in

Washington DC. Sullivan was looking forward to beginning

his new position at Wolfson College at Oxford University. But

fate (and Stergachis) had a different plan.

He presented Sullivan with the vision of a program the

caliber of which had not been seen in outcomes research.

Sullivan was intrigued. When Stergachis showed up—in

person—at Berkeley a few weeks later, Sullivan said yes. “And

then I had to write the most difficult letter of my professional

career. After all, who says ‘no’ to Oxford?” said Sullivan. “But

it changed my life.”

Stergachis reflected, “Sean was the catalyst to carry the

vision of a Ph.D. program forward and to extend the nascent

program into the field of pharmacoeconomics.” With that,

Gardner and Sullivan joined a small group of existing UW

Pharmacy faculty working in pharmaceutical outcomes and

policy that included Dale Christensen and Bill Fassett.

The development of the new Pharmacy Ph.D. program then

began in earnest.

The team began the appeal for external support by writing

grants to study the safety and value of pharmaceuticals

as well as testing the effectiveness of pharmaceutical care

services. They sought national recognition to build program

credibility. They offered workshops about pharmaceutical

outcomes, pharmacoeconomics and drug safety, giving a

multitude of presentations to establish a national identity.

They sought funding to establish an endowment for graduate

students, and began to gain attention and support from a

few forward-thinking pharmaceutical companies, including

Eli Lilly & Company and then-Immunex Corporation.

By 1995, the team had attracted top scholars and built

enough support and funding that the time was right to

secure an official Program designation at the UW as the

Pharmaceutical Outcomes Research and Policy Program

in the Department of Pharmacy. The team submitted the

proposal to the UW for PORPP and its new graduate program

in 1995. By 1997, the first class of Ph.D. students began.

“Andy’s vision took a lot of insight into the future interest in

outcomes and policy research. What he created was ahead of its

time. The hallmark of our program is its proven impact on local

and national policy.” —Sean D. Sullivan

A BLUEPRINT FOR PROGR AM DEVELOPMENT


PORPP: THE BUILDINGA BLUEPRINT FOR PROGRAM GROWTH

Ask any of the four directors of PORPP, Stergachis, Sullivan, Lou

Garrison, or Anirban Basu, and they will tell you that the success

of the program is in its people: Find the best faculty, the best

graduate students, the best post-docs, and the program will

thrive.

New faculty were attracted to the nascent program, including

former FDA scientist Tom Hazlet who began a certificate in

Biomedical Regulatory Affairs (BRAMS) in 1998 that became a

master’s degree program ten years later. With the foundation

built, the reins were handed over to Sullivan who became the

new director, ushering in a new period of growth for the start

up program.

Within a couple of years, new faculty, including former post-

docs Beth Devine and Dave Veenstra, joined. The program was

accredited by the Graduate School. The Corporate Advisory

Board (CAB), comprised of leaders in the pharmaceutical and

managed care industries, had its inaugural meeting, creating

an opportunity for researchers and leaders to share findings,

discuss opportunities and industry needs.

Key partnerships were formed with other organizations

including CHASE Alliance, Hutchinson Institute for Cancer

Outcomes Research at Fred Hutch, Health Services, Group

Health Research Institute, and Premera Blue Cross. These

partnerships continue to provide extraordinary opportunities

for collaborations, data sharing, student and faculty research,

and joint and affiliate faculty appointments.

As partnerships grew, so did endowments and funding. In 2006,

Lou and Fran Garrison established the PORPP Endowed Prize

in Health Policy and Economics in honor of Lou’s parents, Louis

Sr. and Marilyn. Initially funded anonymously, the Prize was

designed to inspire students in PORPP.

After graduating, students became advocates and exemplars

of the excellence for which PORPP has become known. Mitch

Higashi, for example, led an initiative to establish the Health

Technology Fund for PORPP, through a collaboration of

pharmaceutical and health care firms in 2010. Two years later

he and his wife, Mandy, established the Higashi Family Endowed

Fund, a graduate and post-doctoral fellow travel fund within the

PORPP program.

The Certificate in Health Economics and Outcomes Research, a

distance-learning certificate offered through Professional and

Continuing Education began in 2011. The program continues to

thrive and is completely self-sustaining. As of last fall, over 120

students have been trained.

Garrison, Basu and Devine established one of the first Centers

of Excellence in Comparative Effectiveness Research with

funding from the PhRMA Foundation in 2011. The Center

provides advanced training in research methods to PORPP and

Health Services graduate students.

Under Sullivan’s visionary leadership, PORPP joined the Agency

for Healthcare Research and Quality’s (AHRQ) Evidence-based

Practice Center Initiative in 2012, partnering with investigators

at Oregon Health & Science University and Spectrum

Research of Tacoma, WA. First led by Sean and Jerry Jarvik

of UW Medicine’s Department of Radiology, the current site

co-Principal Investigators are Beth Devine and John Gore. (See

separate section in this report)

That same year, Andy and JoAnn Stergachis established the

Stergachis Family Endowed Directorship, ensuring the program

is led by a dynamic and internationally recognized director

and that the legacy of providing each student with specialized

training in outcomes research is strengthened and enhanced.

“Sean took the program to a new level and I think it’s

phenomenal. He did a superb job of institutionalizing the

elements of PORPP that continue to this day and into the

future.”—Andy Stergachis


PORPP: TO THE FUTURE AND BEYONDA BLUEPRINT FOR CONTINUED IMPACT

In 2014, Sullivan was appointed Dean of UW School of Pharmacy

and a national search began for a new Stergachis Family

Endowed Director for PORPP. In May 2015, the successful search

concluded with the selection of Anirban Basu, Ph.D.

At the time, Basu was a Professor of Health Services and an

Adjunct Professor of Pharmacy and Economics. He continues

affiliations with Health Services and Economics and co-directs

the Program in Health Economics and Outcome Methodology

(PHEnOM), a joint program between Departments of Health

Services and PORPP. “He is a well-established researcher

and mentor,” said Lingtak-Neander Chan, Interim Chair for

the Department of Pharmacy. “His work in comparative

effectiveness and health economics research is internationally

recognized.”

Shortly after his appointment, Basu, Veenstra, and Josh Carlson

got word of their $3M grant, funded by the National Heart,

Lung, and Blood Institute (NHLBI) of NIH. They will develop

a comprehensive toolkit of pragmatic value of information

approaches and the corresponding software that can readily be

used by clinical researchers and funders to estimate the value

of randomized clinical trials.

“Dr. Basu is an incredible, dynamic leader and one of the

brightest minds in the field. He is just the right person to take

PORPP to its next level of growth: continuing its stability by

creating opportunities for our junior faculty, students, and post-

docs; growing partnerships with industry; and informing public

policy with world-class research.”—Sean Sullivan

The future of PORPP is bright and wide open, poised to

address many global and national challenges: from continued

opportunities to inform national policy, to creating research

to support the implementation of the Affordable Care Act

and triple aim health care, to guiding best practices with the

increase in personalized medicines, to understanding how

human behavior affects medication adherence and clinical

results, to the rise of technology in healthcare, to growing the

international platform and linking with the important work

done in the Global Medicines Program. “There are so many

career paths for our graduates. It’s more important than ever

that they understand the global marketplace,” notes Stergachis.

“I feel very fortunate to be selected as the director of PORPP.

I think so highly of the PORPP faculty and students. We are

primed to make excellent strides in the coming years in the field,

including and beyond pharmaceuticals. I am excited to work with

the faculty and students and see what we can do together in the

next five to ten years.”—Anirban Basu


PORPP: THROUGH THE EYES OF A POST-DOC As early as 1999, PORPP had established a great reputation and Beth Devine sought a post-doc opportunity in the program. “I was drawn to the opportunity to work with Sean and Andy at UW and Lou [Garrison] who was then at Roche. The coursework of biostatistics, epidemiology, decision analysis, and health policy was exactly what I was looking for as a next step in my career.”

As with many PORPP students and post-docs, Beth benefited from the program’s outreach to industry, obtaining a fellowship that included a year of coursework and a year of applied research at Roche Pharmaceuticals. She studied the cost-effectiveness of interferon-ribavirin for the treatment of hepatitis C; completed a study of patients to elicit their preferences for diabetic neuropathy, and completed several systematic reviews that summarized the psychometric properties of patient-reported outcome instruments to assess treatment outcomes for a variety of disease states, including depression and sleep apnea.

Devine had such a positive experience as a post-doc that she wanted to return as a faculty member. “The program has grown in many ways,” she notes. “We have hired additional faculty. Our students continue to be shining stars, our projects are varied and interesting, and we have superb collaborations with colleagues both inside and external to the UW.”

8 PHARMACEUTICAL OUTCOMES RESEARCH & POLICY PROGRAM PORPP8 PHARMACEUTICAL OUTCOMES RESEARCH & POLICY PROGRAM PORPP8

UNIVERSITY OF WASHINGTON SCHOOL OF PHARMACY 9UNIVERSITY OF WASHINGTON SCHOOL OF PHARMACY 9

CLASS OF 1998

David Smith, RPh, MHA, PhDSenior Investigator Center for Health Research Kaiser Permanente Portland, OR

CLASS OF 2001

Nathorn Chaiyakunapruk, PharmD, PhDProfessor of Health Economics School of Pharmacy Monash University Malaysia, Malaysia

Mitchell Higashi, MBA, PhDChief Economist GE Healthcare Milwaukee, WI

Todd Lee, PharmD, PhDAssociate Professor & Co-Director, Center of Pharmacoepidemiology & Pharmacoeconomics Research Department of Pharmacy Systems, Outcomes & Policy University of Illinois, Chicago

Holly Trautman, PharmD, MSChief Operating Officer Aventine Consulting, LLC Boston, MA

CLASS OF 2002

Denise Boudreau, MPH, PhDSenior Scientific Investigator Group Health Research Institute Affiliate Professor, Department of Pharmacy University of Washington Seattle, WA

Christopher Flowers, MD, MSAssociate Professor, Department of Hematology & Medical Oncology Director, Lymphoma Program, Winship Cancer InstituteEmory University Atlanta, GA

CLASS OF 2003

Brian Custer, MPH, PhDInvestigator Blood Systems Research Institute San Francisco, CA

Nina Hill (Oestreicher), PhDExecutive Director, Health Economics & Outcomes Research Relypsa San Francisco, CA

Kristin Marciante, PhDTacoma, WA

Karen Smith, MS, PhDAssociate Professor of Pharmacy Practice School of Pharmacy Regis University Denver, CO

PAST ALUMNI


WHERE THEY ARE NOW


PAST ALUMNI Continued

CLASS OF 2004

Dana Hurley, PharmD, MSDana Hurley Consulting Biotechnology & Health Economics & Outcomes Research Consultant Seattle, WA

CLASS OF 2005

Scott Strassels, PharmD, PhDManager, Health Economics & Outcomes Research Mallinckrodt Pharmaceuticals St. Louis, MO

CLASS OF 2007

Jennie Best, PhDPrincipal Health Economist Genentech San Diego, CA

Ronald Caldwell, Jr., MS, PhDLecturer III, Department of Economics University of Michigan Ann Arbor, MI

Jonathan Campbell, PhDAssistant Professor, Health Sciences Center University of Colorado Denver, CO

Matthew Kerrigan, PhDPrincipal Scientist PHMR Associates Slovenia

Sarika Ogale, PhDPrincipal Health Economist Genentech San Francisco, CA

CLASS OF 2008

Lisa Meckley, PhDAssociate Director, Health Economics & Outcomes Research Baxalta Boston, MA

CLASS OF 2009

Deborah Atherly, RPh, MPH, PhDSenior Health Economist & Policy OfficerPATH Seattle, WA

Jamie Cross, PhDDirector, Regulatory Affairs Medivation Senior Regulatory Program Director Genentech San Francisco, CA

Eldon Spackman, PhDResearch Fellow, Centre for Health Economics University of York York, United Kingdom

Jelena Zurovac, MS, PhDHealth Researcher, Economist Mathematica Policy Research New York, NY

CLASS OF 2010

Joseph Babigumira, MBChB, PhDAssistant Professor, Global Health Adjunct Assistant Professor, Pharmacy University of Washington Seattle, WA



Lisa Bloudek, PharmD, MSAssistant Director, Global Health Economics Xcenda Seattle, WA

Patrick Gillard, PharmD, MSGlobal HEOR Director, Infectious Disease Allergan Irvine, CA

Bernardo Goulart, MD, MSActing Instructor/Affiliate Investigator Fred Hutchinson Cancer Research Center Seattle, WA

Catherine Waweru, PhDSenior Manager Medtronic Minneapolis, MN

CLASS OF 2011

Vincent Lin, PharmD, MSManager, Global Health Economics, Oncology Amgen Los Angeles, CA

Justin Robertson, MS, PhDActing Assistant Professor, Health Services University of Washington Seattle, WA

William Wong, PharmD, MSSenior Health Economist Genentech San Francisco, CA

CLASS OF 2012

Mindy Cheng, PhDSenior Manager, Global HEOR Abbott Vascular Santa Clara, CA

Ryan Hansen, PharmD, PhDResearch Assistant Professor Department of Pharmacy University of Washington Seattle, WA

Hiep Nguyen, MPH, MSDirector, HEOR AstraZeneca Philadelphia, PA

Joshua Roth, MHA, PhDAssistant Member Fred Hutchinson Cancer Research Center Affiliate Assistant Professor University of Washington Seattle, WA

Joanna Sanderson, PharmD, MSIndependent Consultant, Pharmacoeconomics & Outcomes Research Seattle, WA

Veena Shankaran, MD, MSAssistant Professor Medical Oncology School of Medicine University of Washington Seattle, WA

Jonathan Watanabe, PharmD, MS, (2008), PhDAssistant Professor, Skaggs School of Pharmacy University of California San Diego San Diego, CA

“PORPP has taken a broad and growing field and given me a family

within it. That family really came through for me when I was in need,

and I hope to be able to carry on that tradition.”

Christopher Wallick, PharmD, MS, 2013



PAST ALUMNI Continued

OUR PRESENT

Heidi Wirtz, PharmD, PhDManager, Center for Observational ResearchAmgen Seattle, WA

CLASS OF 2013

Rafael Alfonso, MD, PhD Director, Value Evidence Analytics GlaxoSmithKline Philadelphia, PA

Sara Forrester, PharmD, MSUtilization Management Coordinator Group Health Cooperative Seattle, WA

Zsolt Hepp, PharmD, MSManager, Global Health Economics & Outcomes Research Allergan Irvine, CA

Nita Khandelwal, MD, MSActing Assistant Professor Anesthesiology & Pain Medicine School of Medicine University of Washington Seattle, WA

Christopher Wallick, PharmD, MSManager, HEOR Avanir Pharmaceuticals Costa Mesa, CA

CLASS OF 2014

Preeti Bajaj, PhDHealth Economist, BioOncologyGenentechSan Francisco, CA

Carlos Gallego, MD, MSActing Instructor, Medical Genetics School of Medicine University of Washington Seattle, WA

Katharine Gries, PharmD, MS (2009), PhDSenior Research Associate Evidera Seattle, WA

Norio Kasahara, MPH, PhDDeputy Chief of Party Management Sciences for Health Kabul, Afghanistan

Tracy Yep, PharmD, MSUW/Allergan Post-Doctoral Fellow Allergan Irvine, CA

“The more I progress in my career the more

grateful I become for the strong training I received

at PORPP, with just the right combination of rigor

and pragmatism. I feel like I am standing on the

shoulders of giants, not only because of this unique

training but also for the very strong network among

PORPP folks.”

Nina Hill, PhD, 2004



OUR PRESENT

Our Present

14 MISSION

15 JUNIOR FACULTY RYAN HANSEN, PHARMD, PHD

16 ACADEMIC PROGRAMS16 PHD, PHARMD/MS & FELLOWSHIPS17 CERTIFICATE IN HEALTH ECONOMICS & OUTCOMES RESEARCH 18 CERTIFICATE IN COMPARATIVE-EFFECTIVENESS19 BIOMEDICAL REGULATORY AFFAIRS PROGRAM

20 RESEARCH HIGHLIGHTS20 PACIFIC NORTHWEST EVIDENCE-BASED PRACTICE CENTER22 RESEARCH PRIORITIZATION: INVESTING WISELY IN HEALTHCARE TECHNOLOGY RESEARCH24 THE 2ND PANEL ON COST-EFFECTIVENESS IN HEALTH & MEDICINE

25 ACADEMIC PARTNERSHIPS25 CAB STRATEGIC PARTNERSHIP 26 CHASE ALLIANCE

27 CURRENT GRADUATE STUDENTS & FELLOWS27 OUR STUDENTS & FELLOWS33 PORPP PRIZE34 ISPOR STUDENT CHAPTER35 ADVANCED METHODS

36 GRADUATE TRAINING36 AHRQ T3237 AHRQ PCOR K12

38 PAST YEAR ACHIEVEMENTS38 AWARDS39 SERVICE 40 STUDENT PUBLICATIONS & PRESENTATIONS42 FACULTY PUBLICATIONS 46 FACULTY GRANTS

47 GIFTS


OUR MISSION

» CONDUCT RESE ARCH ON THE EFFECTS AND USES OF

PHARMACEUTICALS IN HUMAN POPUL ATIONS

» PROVIDE GR ADUATE AND POSTGR ADUATE TR AINING IN

PHARMACEUTICAL OUTCOMES RESE ARCH AND POLICY

» DISSEMINATE TIMELY INFORMATION REGARDING

PHARMACEUTICAL OUTCOMES RESE ARCH AND

POLICIES TO GOVERNMENT, THE PHARMACEUTICAL

INDUSTRY, HE ALTH CARE PROVIDERS, AND THE

GENER AL PUBLIC

» INFORM, THROUGH RESE ARCH AND SCHOL ARSHIP,

REGIONAL AND NATIONAL POLICIES GOVERNING

PHARMACEUTICALS AND PHARMACEUTICAL SERVICES

» BE CONSIDERED A RESOURCE FOR INDUSTRY

RESE ARCH, CONSULTATION, AND TR AINING

PARTNERSHIPS



Dissertations don’t typically make the evening news. Unless

you are PORPP alumnus and Research Assistant Professor

Ryan Hansen whose study on the impact of sleeping aids

on motor vehicle accidents was published in the American

Journal of Public Health in June and were featured in an NBC

Nightly News broadcast.

The study grew out of a conversation with a family friend

when Hansen was seeking a dissertation topic some years

ago. The friend said that he had taken a sleep aid the night

before, woke up in the kitchen, and noticed a bite was taken

from a piece of raw pork in the fridge.

“As a pharmacist and a researcher, that had me wondering

about the affect these sleep aids have and how we might

measure their impact.” He identified a way to link motor

vehicle crash records with prescription drug data and

identified a trend among people who had new sleep-aid

prescriptions for these three drugs.

Three prescription sleeping aids are associated with an

increase in motor vehicle crashes, according to his research

in collaboration the Group Health Research Institute. They

found the risk of motor vehicle crashes was nearly double

among new users of the medications temazepam (Restoril),

zolpidem (Ambien, Ambien CR) and trazodone (Desyrel).

Study participants met the following criteria: had a drug

benefit through Group Health Cooperative; were between 21

and 79 years old; were Washington state residents; and had

Washington state driving licenses.

The population’s medical encounters and prescription

records were combined with Washington state driver’s

license records and motor vehicle crash records.

For new users of all three prescriptions, exposure nearly

doubled the risk of vehicle crashes. For new users, the increased

risk could last for up to one year of continuous prescription-

filling. Among the three drugs analyzed, temazepam appeared

to offer the least risk for motor vehicle crashes, but may have

other associated risks for some patients.

“THERE’S A PUBLIC SAFETY CONCERN THAT WE WANT HEALTH

PROVIDERS AND THE GENERAL PUBLIC TO BE AWARE OF,”

SAID RYAN HANSEN, SHOWN HOLDING THE PRESCRIPTION

DRUGS INVOLVED IN THE STUDY.

“Depending on an individual’s need to drive regularly,

combined with a medical indication for sedative use,

the choice of a particular sedative may affect the risk of

crashing,” the scientists wrote. “Prescribers, pharmacists

and patients should discuss this potential risk and consider

the implications of this analysis when selecting a sedative

hypnotic medication.”

“There are many approaches to the management of

insomnia, including lifestyle changes such as cutting caffeine

intake and exercising, which may alleviate the insomnia

without medications,” Hansen said. “There’s a public safety

concern that we want health providers and the general public

to be aware of.”

The team emphasized the need for additional research

to evaluate the risks and associations between overall

medication use and traffic crashes. Noted Hansen:

“People with questions or concerns about a new sleep aid

prescription should talk with their physician, pharmacist, or

health provider to understand the risks.”

JUNIOR FACULTY

RYAN HANSEN’S DISSERTATION RESEARCH FEATURED ON NBC NIGHTLY NEWS



PHARMD/MS CONCURRENT DEGREE

The Department of Pharmacy offers a combined PharmD-

M.S. program in Pharmaceutical Outcomes Research and

Policy. This program is targeted towards outstanding

students currently enrolled in the School of Pharmacy’s

PharmD program who have a proven interest in the field of

Outcomes Research and Policy.

The concurrent degree program allows students enrolled

in the School of Pharmacy’s professional program to

pursue a PharmD and M.S. degree, and to complete both

degrees within a 5-year period. Students will complete

extensive graduate coursework in 4 quarters. The program

offers efficient and specialized training through research

experience, and classroom training.

The demand for clinically trained students with outcomes

research capabilities is high in academic, industry, and

government settings and continues to grow. The PharmD-

M.S. program was created to meet this demand.

FELLOWSHIPS

The University of Washington/Allergan Fellowship

and the University of Washington/Bayer Fellowship in

Pharmaceutical Outcomes Research and Policy combines the

resources of a leading academic center for pharmaceutical

economics and policy with the dynamic, real-world training

of two major pharmaceutical companies recognized for their

commitment to innovation.

Postdoctoral fellowship students work closely with Program

faculty on projects where they learn first-hand how to apply

the principles of outcomes research to real-life problems.

These fellowships provide students with a year of study at

the University of Washington, leading to a master’s degree,

combined with a period of applied research at the sponsoring

company.

PHD IN PHARMACEUTICAL SCIENCES

The University of Washington created the Pharmaceutical

Outcomes Research and Policy Program (PORPP) in 1995

to strengthen research efforts and provide graduate-level

training in the outcomes research and policy areas.

Pharmaceutical outcomes research employs a variety of

methods to evaluate the impact of healthcare interventions

on clinical outcomes, patient quality of life, cost-effectiveness

and assessment of healthcare policy implications. The

graduate program in pharmaceutical outcomes research

and policy trains students in economic evaluation,

pharmacoepidemiology, health services and policy research

and health technology.

Graduate training in the program prepares students for

career opportunities in:

• Academic research and teaching

• Safety and economic evaluation of products in the pharmaceutical, biotechnology and medical device industries

• Policy analysis for professional associations, health care insurance providers, and governmental agencies

• Management within hospitals, managed care organizations and programs concerned with reimbursement for pharmaceuticals and other medical technologies

ACADEMIC PROGRAMS

PHD, PHARMD/MS & FELLOWSHIPS



The Certificate in Health Economics and Outcomes Research

program is entering its 4th year. Launched at the start

of the 2012-2013 academic year in conjunction with the

UW Professional and Continuing Education program, this

distance learning program is designed for professionals

working in health care settings including payer organizations,

health insurance industry, government, the life sciences,

pharmaceutical and biomedical industries, and for

professionals working within Health Technology Assessment

or reimbursement organizations. The program offers one

course per academic quarter--Fall quarter: Principles of

Health Economics, taught by Lou Garrison and Anirban

Basu; Winter quarter: Economic Evaluation, taught by

Dave Veenstra and Josh Carlson; Spring quarter: Practice

of HTA in a Global Environment, taught by Sean Sullivan

and Beth Devine. During the program, students learn the

key economic concepts and analytical tools of human

economic behavior, explore the current state-of-the-art in

the economic evaluation of health care technologies, and are

introduced to the principles and methods of HTA practice.

Students work in groups throughout the program on a

capstone project, which applies their learning to an assigned

country. Student evaluations have been positive. Many of

the students are international, a testament to the program’s

global reach.

In the second year of the program, applications were at 75+

and in the third year applications were at 90+. The 2015-

2016 program is on target to reach similar numbers. The

program now has an active LinkedIn alumni group. Courses

are continually being updated and revised to keep pace with

changing technologies and economies. Revenues from the

Certificate in Health Economics and Outcomes Research

program support 1-2 PORPP teaching assistant positions

each year.

http://www.pce.uw.edu/certificates/health-economics.html

for additional information.

ACADEMIC PROGRAMS

CERTIFICATE IN HEALTH ECONOMICS AND OUTCOMES RESEARCH

“Joining PORPP was a life-changing experience

and dream come true for me. By interacting

with some world-renowned health outcomes

researchers, I learnt to think analytically and seek

creative ways to tackle real-life problems. These

are learnings that I continue to apply to this day.”

Catherine Waweru, PhD, 2010


Led by Beth Devine, Lou Garrison, and Anirban Basu, the

UW has now completed the third year of the UW Center of

Excellence in Comparative Effectiveness Research (CER), the

cornerstone of which is the Graduate Certificate in CER. The

UW Center of Excellence in CER is one of the first two (along

with Hopkins) of six academic centers across the US that

received support from the Pharmaceutical Research and

Manufacturer’s Association (PhRMA) Foundation through a

competitive request for proposals offered between 2011 and

2014.

The UW Certificate is open to currently enrolled PhD and MS

students in PORPP and Health Services. Coursework beyond

the core work required for each degree prepares enrolled

students to conduct projects that use advanced skills in

observational data analysis and decision sciences, preference

(utility) estimation from patient reported outcomes data,

network meta-analysis, and Bayesian statistics. To date,

ten students have registered to complete the Certificate.

Three of these have been supported by the formal research

assistantships; an additional five have each received a

$10,000 dissertation stipend. See http://sop.washington.

edu/department-of-pharmacy/pharmaceutical-outcomes-

research-policy-program-porpp/certificate-programs/

for additional information. We are grateful to the PhRMA

Foundation for their support in training our students.

The UW Center for Excellence in CER has led to two

new initiatives, now underway: 1) a stakeholder-driven

educational and experiential training program to prepare

scientists and clinicians to conduct CER/PCOR in the WWAMI

(Washington, Wyoming, Alaska, Montana, Idaho) region,

with a focus on American Indians and Alaska Natives, and 2)

a certificate program in Translational Sciences. The first is

supported by a grant from AHRQ, with Larry Kessler as PI; the

second is supported by the Institute of Translational Health

Science (UW CTSA), with Beth Devine as Lead Faculty.

In early 2014, Beth Devine and Lou Garrison joined Jodi Segal

of Johns Hopkins in leading a national invitational conference

titled, “Curricular Advances for Patient-Centered CER”. 120

attendees representing 50 academic institutions, the life

sciences industries, the Federal government, professional

organizations and health plans discussed approaches used

to prepare a workforce skilled in CER and patient centered

outcomes research (PCOR). The conference was supported by

grants from AHRQ, PCORI, and the PhRMA Foundation.

In early 2015, the PhRMA Foundation engaged Avalere Health

LLC to conduct a program evaluation of the CER initiative.

Report findings indicate the initiative has accomplished the

original objectives in providing seed funds for academic

training programs for CER. The report recommends that

the PhRMA Foundation conduct a follow up conference that

would be co-sponsored by AHRQ and PCORI, as well make

use of webinars and other innovative teaching platforms to

advance educational efforts for healthcare professionals and

other ‘users’ of CER. As a member of the PhRMA Foundation’s

CER Advisory Committee, Beth will participate in these

activities.

ACADEMIC PROGRAMS

UW CENTER OF EXCELLENCE IN COMPARATIVE EFFECTIVENESS RESEARCH


Educators (AGRE), incorporated in 2014. AGRE provides a

forum for the ~40 graduate programs in regulatory affairs,

in the US and abroad, to discuss issues of common concern

and share best practices for regulatory education. As an

early step, AGRE members developed and have published

a set of core competencies expected for graduates of MS

programs in regulatory affairs and regulatory science. Initial

analysis shows that the BRAMS curriculum covers the core

competencies well.

Our students are educated about regulatory issues for drugs,

devices, and biologics. Training focuses primarily on the

US regulatory system but considerable content is included

on international regulatory systems. The practicum gives

them real-world experience doing a regulatory project at

a company, institution or non-profit organization. About

140 students have enrolled in the BRAMS program and we

expect our 100th graduate early in 2016. Graduates of the

BRAMS program are well-rounded regulatory professionals

who are able to contribute in multiple elements of product

development for national and international markets. They

are employed throughout the US and abroad (Canada,

India, China, and Taiwan) in pharmaceutical, biologic, and

medical device companies, and in universities, blood banks,

regulatory agencies, and other non-profit organizations.

They have both leadership and supporting roles in pre-

clinical and clinical research, quality, regulatory affairs, and

communications.

The 3-quarter certificate program in Biomedical Regulatory

Affairs was developed at the request of local industry and

launched in September 1998. Its core curriculum seeks to

develop an understanding of regulatory process for biologics,

drugs and medical devices; a Clinical Trials Certificate

followed in 2000. Both programs have enjoyed generous

support from industry, the US Food and Drug Administration,

and colleagues in the School of Law and the College of

Engineering. UW Professional & Continuing Education

has been an invaluable partner. Through spring 2015,

331 students have completed the Biomedical Regulatory

Affairs certificate and 385 have completed the Clinical Trials

certificate.

Throughout the early years of the Biomedical Regulatory

Affairs Certificate program, students asked when an

advanced degree would be available. The Biomedical

Regulatory Affairs Master of Science (BRAMS) Degree

program launched in 2008. The BRAMS advisory committee

mandated that the curriculum stress communication skills

and include a practicum. The current curriculum includes

the courses of both certificate series: a two-course technical

writing series; as well as courses in international regulatory

affairs, regulatory data essentials and analysis, medical risk

analysis and management, regulatory affairs skills, and a

9-credit practicum. http://www.regulatoryaffairs.uw.edu/

In concert with other higher education institutions, BRAMS

faculty have been active in the development of a professional

organization, the Association of Graduate Regulatory

ACADEMIC PROGRAMS

THE BIOMEDICAL REGULATORY AFFAIRS PROGRAM


The Pacific Northwest (PNW) Evidence-based Practice Center

(EPC) develops evidence reports and technology assessments

of health care topics for federal agencies and state agencies,

professional associations, foundations, and the US Preventive

Services Task Force. These reviews report the evidence from

clinical research studies and rate the quality of that evidence

for use by clinicians, employers, policymakers, researchers,

and others in decision-making capacities about the provision

of health care services and health research. Reports may

be used to inform the development of clinical practice

guidelines, or to inform reimbursement and coverage

policies. The PNW EPC is one of 13 EPCs sponsored by the

Agency for Healthcare Research and Quality (AHRQ), as part

of the Effective Healthcare Program. First started in 1997, the

AHRQ EPC Program is now in its fifth, 5-year cycle, continuing

the work of previous EPCs. For more information about the

AHRQ EPC program, visit http://www.ahrq.gov/research/

findings/evidence-based-reports/overview/.

The PNW EPC is a partnership between Oregon Health

Science University, the University of Washington CHASE

Alliance (of which PORPP is a participating program), and

Spectrum Research, Inc., of Tacoma, WA. Beth Devine,

Associate Professor in PORPP, and John Gore, Associate

Professor of Urology, are the UW site co-principal

investigators of the PNW EPC, and lead the projects based

at UW. Collectively, investigators with the PNW EPC have a

particular interest in leading health technology assessments

of diagnostic technologies, prevention effectiveness,

evidence-based informatics, research in managed care, and

critical appraisal of cost-effectiveness analysis and decision

analysis. In the past three years, PORPP faculty and staff

have lead or participated in 8 unique EPC projects. For more

information about the PNW EPC, visit http://www.ohsu.edu/

xd/research/centers-institutes/evidence-based-practice-

center/.

To produce reports and technology assessments,

investigators and staff of the Pacific Northwest EPC review

all relevant scientific literature on the clinical, behavioral,

and organization and financing topics awarded under

contract by AHRQ. These reports are completed using

rigorous, comprehensive syntheses and analyses of the

relevant scientific literature. EPC reports emphasize explicit

and detailed documentation of methods, rationale, and

assumptions. These scientific syntheses may include meta-

analyses and cost analyses. All EPCs collaborate with other

medical and research organizations so that a broad range of

experts is included in the development process. In addition,

the EPCs: 1) provide technical assistance to professional

organizations, employers, providers, and policymakers to

facilitate translation of the reports into quality improvement

tools, evidence-based curricula, and reimbursement policies;

2) undertake methods research; and 3) update prior evidence

reports.

Each completed report is published on the AHRQ EPC

website, and is simultaneously published in a high-impact

medical journal, often the Annals of Internal Medicine. Since

joining the Pacific Northwest EPC, investigators in the UW

CHASE Alliance have led and participated in the following EPC

projects.

1) Chou R, Deyo R, Devine B, et al. The Effectiveness and Risks

of Long-Term Opioid Treatment of Chronic Pain. Evidence

Report/Technology Assessment No. 218. (Prepared by the

Pacific Northwest Evidence-based Practice Center under

Contract No. 290-2012-00014-I.) AHRQ Publication No.

14-E005-EF Agency for Healthcare Research and Quality.

Rockville, MD: Agency for Healthcare Research and Quality;

September 2014. Available at: www.effectivehealthcare.ahrq.

gov/reports/final/cfm.

RESEARCH HIGHLIGHTS

PACIFIC NORTHWEST EVIDENCE-BASED PRACTICE CENTER



Chou, R., et al., Imaging Techniques for the Diagnosis of

Hepatocellular Carcinoma: A Systematic Review and Meta-

analysis. Ann Intern Med, 2015. 162(10): p. 697-711.

2) Chou R, Cuevas C, Fu R, et al. Imaging Techniques for

the Diagnosis and Staging of Hepatocellular Carcinoma.

Comparative Effectiveness Review No. 143. (Prepared

by the Pacific Northwest Evidence-based Practice

Center under Contract No. 290-2012-00014-I.) AHRQ

Publication No. 14(15)-EHC048-EF. Rockville, MD: Agency

for Healthcare Research and Quality; October 2014. PMID:

25473698. Available at: www.effectivehealthcare.ahrq.gov.

Chou R, Turner JA, Devine EB, et al. The effectiveness

and risks of long-term opioid therapy for chronic pain:

a systematic review for a national institutes of health

pathways to prevention workshop. Ann Intern Med. 2015 Feb

17;162(4):276-86. PMID: 25581257.

3) Gold LS, Lee CI, Devine B, et al. Imaging Techniques for

Treatment Evaluation for Metastatic Breast Cancer. Technical

Brief No. 17. (Prepared by the Pacific Northwest Evidence-

based Practice Center under Contract No. 290-2012-00014-I.)

AHRQ Publication No. 14-EHC044-EF. Agency for Healthcare

Research and Quality. Rockville, MD: January 16, 2015

October 2014. Available at: www.effectivehealthcare.ahrq.

gov/reports/final.cfm.

Lee CI, Gold LS, Nelson HD, et al. Comparative effectiveness

of imaging modalities to determine metastatic breast cancer

treatment response. Breast. 2015 Feb;24(1):3-11. PMID:

25479913.

4) Chou R, Selph S, Buckley D, Gustafson K, Griffin J, Grusing

S, Gore J. Treatment of Nonmetastatic Muscle-Invasive

Bladder Cancer. Comparative Effectiveness Review No.

152. (Prepared by the Pacific Northwest Evidence-based

Practice Center under Contract No. 290-2012-00014-1.) AHRQ

Publication No. 15-EHC015-EF. Rockville, MD: Agency for

Healthcare Research and Quality; June 2015.

5) Hersh W, Tottan A, Gorman P, Devine EB, Eden K, Kassakian

S, Woods S, McDonagh M, Daeges M, Pappas M. Health

Information Exchange. (Prepared by the Pacific Northwest

Evidence-based Practice Center under contract with AHRQ).

Under review.

Hersh W, Tottan A, Gorman P, Devine EB, Eden K, Kassakian

S, Woods S, McDonagh M, Daeges M, Pappas M. Health

Information Exchange. (under review at J Am Med Inform

Assoc)

Eden KB, Totten AM, Kassakian SZ, Gorman PN, McDonagh

MS, Devine B, Pappas M, Daeges M, Woods S, Hersh WR.

Barriers and facilitators to exchanging health information:

a systematic review of usability. (under review at Int J Med

Inform)

6) Chou R, Hashimoto, R, Friedly J, et al. Pain Management

Injection Therapies for Low Back Pain/Technology

Assessment. (Prepared by the Pacific Northwest Evidence-

based Practice Center under Contract No. 290-2012-00014-I).

Under review.

7) IMPROVING HEALTH SYSTEMS—no publications

8) NONINVASIVE TREATMENT FOR LOW BACK PAIN—still

active


BETH DEVINE


How do we optimize public investments in health research?

In a health care system with limited resources, it is vital

to identify research areas with the greatest likelihood of

influencing clinical practice and improving patient outcomes.

Value-of information (VOI) analysis is a quantitative

approach to inform research prioritization that has received

increased attention, particularly within the context of

comparative effectiveness research.

VOI analysis involves the application of methods from

economics and statistical decision theory in decision

analysis to estimate the humanistic and economic value

of performing additional research to better understand

the safety, efficacy, and cost of technologies and medical

interventions. These analyses quantify how research will

produce information that may change clinical decision-

making and how changes in clinical decision-making improve

patient outcomes. Several factors are considered – how

much and when knowledge will be generated, who will

be impacted by this knowledge and to what extent this

knowledge will translate to better decision-making.

Investigators in PORPP have established a robust research

program at the forefront of this innovative area of research.

Through a series of high-profile related projects we have

developed new methodologies, developed processes for

engaging with and educating key healthcare stakeholders,

and applied these methods and processes to real-world

decision making at the national level. Below we highlight

the projects in more detail and provide a summary of our fi

ndings to date and future directions.

CANCER GENOMICS (RAMSEY, VEENSTRA, CARLSON).

Our first project in the area of research prioritization

using VOI was the Center for Comparative Effectiveness

Research in Cancer Genomics (CANCERGEN), an NIH

funded project with the objective of identifying promising

genomic technologies in the treatment of cancer, prioritize

further research, and facilitate their evaluation in clinical

trials through a collaborative stakeholder driven process.

This project was developed and performed with the Fred

Hutchinson Cancer Research Center (FHCRC), the Center for

Medical Technology and Policy (CMPT) and SWOG (formerly

the Southwest Oncology Group), a large cancer clinical trials

cooperative group. The primary responsibility of the UW

team (led by Dr. Veenstra) was VOI model development and

impact evaluation. This was the first project to directly link

VOI analyses to decision-making processes in the U.S. and

informed clinical trial recommendations and trial designs

within SWOG. This formative work allowed our group to

develop approaches for educating stakeholders about VOI,

advance methods for VOI modeling in real world situations,

and resulted in 8 published manuscripts—setting the stage

for additional work and grants. However, there were a

number of challenges that arose, including the resource

intensity required and time investment needed to build and

present VOI models to the stakeholder group.

CANCER CLINICAL TRIALS (RAMSEY, CARLSON, VEENSTRA, BASU).

Working with the same group of collaborators as in

CANCERGEN, we are advancing applied VOI as part of a PCORI

funded project, ‘A Structured Approach to Prioritizing Cancer

Research Using Stakeholders and Value of Information.’ This

3-year project was launched in Sept. 2013 with the objective

to evaluate the impact of VOI analyses on SWOG’s clinical

trial prioritization processes. This methodology-focused

project intersects stakeholder engagement, VOI, and minimal

modeling to inform research prioritization. The addition

of minimal modeling, a concept previously developed by

Basu and colleagues, enables the rapid VOI modeling efforts

necessary to allow real-time VOI analysis within SWOG. The

UW team, led by Dr. Carlson, is generating VOI estimates

for proposed SWOG trials in real-time, and evaluating the

impact of the VOI estimates on SWOG decision-making within

SWOG’s Executive Committee. Thus far, we have completed

the educational and minimal modeling VOI development

RESEARCH HIGHLIGHTS

RESEARCH PRIORITIZATION: INVESTING WISELY IN HEALTHCARE TECHNOLOGY RESEARCH


phases of the project and are currently in the prospective

VOI evaluation phase. Our preliminary findings indicate that

our process is efficient, feasible, and acceptable to SWOG

members.

PERSONALIZED MEDICINE (VEENSTRA, CARLSON, BASU).

In response to an NIH funding opportunity announcement,

we developed a comprehensive proposal to advance our

work in precision medicine and research prioritization.

The aims of our grant are to 1) Expand the concept of the

expected value of individualized care (EVIC) to represent

an encompassing economic model for prioritizing PM

research and evaluating specific PM technologies, 2) Assess

societal, provider, and payer preferences for PM, including

personal utility and willingness to pay, to inform the EVIC

model, and 3) Develop a pragmatic decision framework

to address evidence uncertainty in PM and inform clinical

guideline and reimbursement policies. This 5-year grant was

launched in the fall of 2013 and will have key contributions

to the advancement of value of information applications

and research prioritization. Advancing the EVIC framework

will allow researchers to prioritize many facets of the

individualization process including – 1) research investments

in developing personalized biomarkers, 2) identification of

factors leading to uptake on these personalized biomarkers

and 3) evaluation of these biomarkers in practice. Further,

aim 3 will assess the value of future research for personalized

medicine (PM) case studies and develop a pragmatic

framework to help decision makers assess ‘insufficient’ vs.

‘sufficient’ evidence in the development of clinical guidelines

and reimbursement policies.

CARDIOVASCULAR CLINICAL TRIALS (BASU, CARLSON, VEENSTRA).

Most recently, we received a grant from the National Heart,

Lung, & BIood Institute, ‘Value Of Information Methods

For NHLBI Trials,’ to develop a comprehensive toolkit of

pragmatic VOI approaches and the corresponding software

that can readily be used by clinical researchers and NHLBI to

estimate the a priori value of RCTs.

This 4-year grant, launched in the spring of 2015, has the

following 4 aims: 1) To assess the feasibility of conducting

minimal modeling VOI calculations in the context of NHLBI

trials, 2) To develop a comprehensive toolkit of minimal

modeling VOI methods for specific questions about an

RCT based on a return-on-investment framework, 3) To

demonstrate the use of the checklist and toolkit developed

in Aims 1 and 2, and 4) To develop user friendly web-

based software as a proof-of-concept to perform these

calculations for an RCT based on inputs received from NHLBI

stakeholders. This work builds directly off of our formative

work and will be the first example of VOI being applied

within a federal funding agency.

PORPP and our collaborators are at the forefront of VOI

methods development and real-world application to inform

research prioritization. We believe that while challenges

remain, VOI is feasible, acceptable to key decision-making

stakeholders, and can impact clinical research prioritization

decisions. Our research group within PORPP and in

collaboration with our partner institutions will continue this

promising line of research, pushing the development of new

methods and pioneering the application of VOI to inform

real-world decision making. Extending these methods to

the commercial side of research investments, throughout

a product lifecycle, is also an active area of our research

portfolio. The ultimate purpose of medical research is to

improve the lives of patients. We hope that our work will

further this goal by allowing research groups and funders

to design and select research studies that maximize the

importance and impact of research investments on the

health outcomes of individuals and populations.

LEFT TO RIGHT: JOSH CARLSON, SCOTT RAMSEY, DAVID VEENSTRA


In 1993, the U.S. Public Health Service convened a panel of

13 non-government scientists and scholars to review the

developing field of cost-effectiveness analysis. In 1996 the

panel published a book that summarized the state of the

field and provided recommendations for the use and conduct

of cost-effectiveness analyses in health and medicine.

Popularly known as the “Gold book”, this report quickly

became a standard reference both in the United States and

internationally and has been cited more than 6,000 times.

Originally thought to have a life expectancy of 10 years, this

report has continued to inform and shape training for future

generations of researchers over the last 20 years.

However, several events occurred since the publication of

this report in 1996. In 1998, The World Health Organization

established the WHO-CHOICE project where teams work with

policy makers at the country level, providing information on

cost-effectiveness, costs and strategic planning which can

help guide policy decisions. In 1999, the National Institute

of Clinical Excellence (NICE) was established in the UK. In

2004, the Institute for Quality and Efficiency in Health Care

(IQWiG) was established in Germany, and the Haute Autorité

de santé (HAS) in France. In 2008, the Advisory Committee on

Immunization Practice (ACIP) established guidelines for the

Center for Disease Control in the US. In 2010, the Affordable

Care Act was passed in the US that explicitly prohibits the

RESEARCH HIGHLIGHTS

THE 2ND PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE

newly created Patient-centered Outcomes Research Institute

(PCORI) to develop cost per QALY thresholds. In 2014, the

Gates reference case for economic evaluation was published.

In light of the substantial developments of the theory, and

methods around economic evaluations and especially cost-

effectiveness analysis, a second panel on cost-effectiveness

analysis was convened in 2013 by a mix of leaders in the

field, which includes members of the original Panel (Ted

Ganiats, Joanna Siegel and Louise Russell) and also new

members (Peter Neumann and Gillian Sanders). This

leadership group put together a team of experts to review

all facets of cost-effectiveness theory and methods and

to develop a report updating the original panel’s work.

The panel members have been meeting over the last two

years to debate and discuss many issues that relate to the

development and application of CEA methods. Further

details on this panel can be found at http://2ndcep.hsrc.

ucsd.edu/

Anirban Basu serves as a panelist in this group and is leading

the chapters on costs and discounting. He is also a co-author

on the chapters on theoretical foundations and uncertainty.

Chapters will be available for public review later this year on

the panel website. Expected publication of the final report is

Spring 2016.

ANIRBAN BASU


The UW School of Pharmacy Corporate Advisory Board (CAB)

first met 17 years ago, in 1998, to identify areas of common

interest between PORPP and corporate members of the

pharmaceutical, biotech, and device industry. In November

2001, the CAB was reconvened, and eleven colleagues from

industry met with PORPP faculty for a day of brainstorming

ideas to enhance an already strong partnership, with the

goal of strengthening the PORPP program to meet the

needs of colleagues in the pharmaceutical industry. Our

mutually identified goals were to: 1) Train researchers who

understand the perspective of, and are prepared to function

at a high level within industry; 2) Increase the number of

PORPP graduates to fill available positions in industry; 3)

Develop the ability to respond to emerging industry research

needs, both in terms of expertise of our graduates, and in

terms of faculty to conduct research in emerging areas; and

4) Train those currently employed in the industry setting

in the concepts of pharmacoeconomics and outcomes

research.

Held annually since 2001, the CAB meeting is now an

integral part of PORPP activities and is an event that is much

anticipated. The morning of each CAB meeting is structured to:

• Provide our corporate partners an update on activities and accomplishments of the PORPP faculty, students and post-doctoral fellows;

• Highlight new research programs, accomplishments, and academic offerings.

• The afternoon session provides a more informal opportunity for:

• Discussion between PORPP faculty and corporate colleagues to assess progress in areas of common endeavor;

• Identify ongoing gaps in reaching common goals;

• Celebrate mutual successes.

The student poster session, held during the end-of-day

wine reception provides an opportunity for our corporate

colleagues to appreciate how their generous contributions

to our graduate program are preparing PORPP students to

become industry-employed scientists of the highest caliber.

A review of the minutes of the 2002 CAB meeting suggest that

PORPP faculty were already making progress in achieving

the four goals outlined in 2001. Over time, our goals have

remained largely the same, modified to fit rapidly evolving

times. A graduate seminar was instituted; themed quarterly

and held weekly. Since then, presentations and discussion of

myriad topics suggested by CAB have been presented – from

enhancing business communications to strategic planning,

from global health to drug safety. Collaborative PORPP/

industry pre- and post-doctoral fellowships were established,

as were opportunities for students to complete summer

internships in industry. Several important training programs

and research projects have also resulted from our strategic

partnership with our corporate colleagues – many under the

umbrella of the Health Tech Fund. These activities include the:

• Creation of a global database in which facts are recorded about risk-sharing agreements;

• Evaluation of the impact of health economics and outcomes research;

• Evaluation of a value-based insurance design at the payer level;

• Development of an online certificate program in health economics and outcomes research;

• Assessment of the value of a cure.

For the 2014 CAB meeting, PORPP hosted 26 corporate

colleagues, a true reflection of the growth of our partnership

over time. We look forward to the continued successes of this

important component of PORPP

ACADEMIC PARTNERSHIPS

CAB HISTORY


The UW Centers for Comparative and Health Systems

Effectiveness (UW CHASE Alliance) was developed to

facilitate multidisciplinary, high impact comparative and

systems effectiveness research and implementation. The

CHASE Alliance consists of UW researchers and community

partners interested in comparative effectiveness research,

health disparities, health system evaluation, technology

assessment, patient-centered outcomes, economic

evaluation, and dissemination and translation. The mission

of the UW CHASE Alliance is to provide the multidisciplinary,

collaborative environment required for the successful

conduct and implementation of comparative effectiveness

research in today’s and tomorrow’s complex health care

system.

The graduate programs of PORPP support the objectives

of the CHASE Alliance. The programs cross the major

health science divisions of the UW, representing nationally

and internationally recognized academic programs in

Pharmacy, Public Health, and Medicine. All of the degrees

and certificates consist of cohesive training through

completion of didactic course offerings and participation

in pragmatic research and implementation opportunities

in ongoing, funded projects with the UW and our

ACADEMIC PARTNERSHIPS

UW CHASE ALLIANCE

partnership organizations. It also involves participation with

stakeholders in real-world settings. Our CHASE partnership

institutions include the Fred Hutchinson Cancer Research

Center, Group Health Research Institute, and the VA Puget

Sound Health Care System.

The leadership of the CHASE Alliance includes six faculty

members who hold appointments within the Department of

Pharmacy – PORPP division.

“I have been grateful to be a family member of

PORPP. My experience with PORPP has been

wonderful. It strongly influences not only my career

development but also my life and what I have become

myself today. I am pleased to see the success of

PORPP on this 20th year anniversary.”

Nui Nathorn Chaiyakunapruk PharmD, PhD, 2001


Blythe Adamson, MPH

Blythe progressed through

the core PORPP curriculum in

her first year supported by an

NRSA T32 fellowship from the

Agency for Healthcare Research

Quality. Under the mentorship

of Dr. Lou Garrison, Blythe

continues to unpack static and

dynamic model choices for

economic analyses of infectious

diseases. She presented posters on the cost-effectiveness of

HIV vaccines at the Western Pharmacoeconomics Conference

in Denver and International Society for Pharmacoeconomics

and Outcomes Research Meeting in Philadelphia. After

passing the preliminary exams, Blythe was supported by

funding from the Center for AIDS Research to attend a

three-week Summer Institute in Statistics and Mathematical

Modeling of Infectious Diseases.

Maria Agapova, MSc, PhD Candidate

Maria is completing work

on her dissertation project,

A Benefit-Harm Assessment

Framework for Development of

Clinical Guidelines in Diagnostic

Radiology. She presented this

work to the Department of

Pharmacy Corporate Advisory

Board last fall. This summer,

Maria lead the Department’s

first multi-criteria decision analysis with a group of

Emergency Department physicians and radiologists. Maria

also led to publication in Expert Reviews of Pharmacoeconomics

and Outcomes Research, a cost-analysis for the Irish National

Screening Service of two testing schedules for cervical

cancer surveillance. In the very near future, Maria looks

forward to transitioning to the workforce where she can be

actively involved in healthcare policy implementation while

gaining pragmatic experience in decision analysis for policy

development.

Mark Bounthavong, PharmD, MS

Mark is in his second year of the

Agency for Healthcare Research

and Quality T32 predoctoral

trainee grant. Mark has been

working with Drs. David

Veenstra and Beth Devine on

performing a network meta-

analysis and cost-utility analysis

for FDA-approved biologics

in moderate-to-severe Crohn’s disease. He presented his

research at the Western Pharmacoeconomics and Outcomes

Research Conference (WPC) and at the International Society

for Pharmacoeconomics and Outcomes Research. At the

WPC, he received the best podium presentation award. He

also shared the annual PORPP prize (with Vanessa Shih) for

his work on evaluating the cost-effectiveness of biologics in

Crohn’s disease. In the past year, Mark evaluated the cost-

of-illness of Crohn’s disease in the US population, which he

presented at the National Research Service Award meeting.

He is currently working on his dissertation topic that focuses

on the economic and clinical outcomes of the herpes zoster

virus vaccine in the Department of Veterans Affairs.

CURRENT GRADUATE STUDENTS & FELLOWS

STUDENTS



Will Canestaro, MS, PhD Candidate

Will is entering his fourth

year of the PhD program

and has recently passed his

general exam and moved on to

candidate status. The focus of

his research will be developing

methods to estimate societal

economic loss from publication

bias. Will has also spent the

past year serving as the research assistant for the federally-

funded PriMER study, for which Drs. Carlson and Veenstra

are both principal investigators. Will will be completing his

dissertation research with support from competitive grants

from the PhRMA Foundation and American Foundation for

Pharmaceutical Education.

Amy Cizik, MPH PhD Candidate

Amy completed her general

exam in March 2014 to become a

PhD candidate. Her dissertation

is entitled, “Variations in Surgeon

Treatment Preferences and The

Impact on the Cost-Utility of

Surgery for Soft Tissue Sarcoma”.

This work focuses on surgeon

preferences for health states for

the treatment of soft tissue sarcoma. In the upcoming year

she will be working to successfully defend her final dissertation,

while serving as a lead investigator on a NIH/NIAMS funded

project to better understand patient non-response to spine

fusion surgery. As a research scientist in the Department of

Orthopaedics and Sports Medicine she continues to collaborate

and author papers with orthopaedic surgeons on the topics of

surgical site infection of the spine and quality of life measures in

sarcoma.

Devender Dhanda, BSPharm, MS, MBA

Devender will be entering his

third year of the PhD program in

PORPP. By the end of the second

year, Devender completed

his required coursework and

passed all four prelims required

by the program. During the

second year, he worked with

Dr. Dave Veenstra on the

Personalized Medicine Economics Research (PRiMER) grant.

Devender worked on evidence comparison between the

pharmacogenomics-based and clinical decisions based on

drug-drug interactions by running value of information analysis

(VOI) of the warfarin amiodarone drug-drug interaction and

pharmacogenomics based warfarin dosing. Devender also

worked on the Bayesian Meta-analysis of Safety Endpoints of

the Novel Anticoagulants (NOACs) and a Systematic Review of

Disease Specific Patient Reported Outcomes in Atrial Fibrillation

with Dr. Beth Devine. During his third year, Devender is

exploring dissertation topics for his PhD dissertation and plans

on submitting the short proposal by end of winter quarter.


STUDENTS Continued



Simrun (Simi) Grewal, MHS

During her first year in

the PhD program, Simi

enjoyed opportunities

working with faculty on

various topics including

international financing for

non-communicable diseases

and evolving health technology

assessment processes in

middle income countries. Over the summer, Simi gave an

oral presentation of her research using a discrete choice

experiment to explore health insurance preferences at

the International Health Economics Association (iHEA)

Congress in Milan. She also completed an internship in

Health Economics and Outcomes Research with a focus

on oncology at Genentech in San Francisco. Her work on

national immunization program costing was published in

Vaccine. Entering her second year, Simi is excited to continue

learning about personalized medicine and stated preferences

research methods as an RA on the Personalized Medicine

Economics Research (PRiMER) project.

Katelyn Keyloun, PharmD, Allergan Post-Doctoral Fellow 2014-2016

Katelyn is a Washington State

pharmacist (Graduated from

University of Washington, June

2014) coming to the Fellowship

program with a background in

parasitology research. She has

completed rigorous coursework

through the Department of Pharmacy at UW this past year,

including core coursework in epidemiology, biostatistics,

and in health economics and outcomes research. Working

towards earning a Master of Pharmaceutical Sciences degree,

her in-progress thesis project, a retrospective analysis of

US insurance claims data, is titled “Adherence Outcomes to

Antidepressant Medication Therapy in Patients with Major

Depressive Disorder”. She is excited to work on research

projects supporting Major Depressive Disorder and other

therapeutic areas for Allergan’s Global Health Outcomes

Strategy and Research department.

Richard Kim, MD, MS, PhD Candidate

This past year, Richard

successfully completed his

General Examination for

his Ph.D candidacy. His

dissertation will look at

organizational factors that

are associated with favorable

clinical outcomes and costs

in the lung cancer diagnostic

workup. He also completed

a project funded by the Firland Foundation, looking at the

epidemiology and treatment variation in non-tuberculous

mycobacterial infection. He presented these findings at the

2015 international conference for the American Thoracic

Society. This coming year, he hopes to complete his

dissertation and continue to find opportunities that combine

his clinical and research endeavors.




STUDENTS Continued

Meng Li, MS

Meng completed her second

year in the PhD program, and

successfully completed all

of her required coursework.

During the past year, Meng

has been working with Drs.

Lou Garrison and Joseph

Babigumira on the economic

burden of giant cell arteritis

in the United States. She

also worked with Dr. Ryan Hansen and surgeons from the

School of Medicine on two clinical studies of liver transplant

patients. She has also been working with Dr. Hansen and

researchers from the UW Alcohol & Drug Abuse Institute on a

project that describes opioids use in Washington State under

the Prescription Monitoring Program. This summer, she is

working with Dr. Andy Stergachis on a survey of corporations

and non-government organizations on their medication

donation programs.

Solomon Lubinga, BPharm, MSc

Solomon is entering the fourth

year of the PhD program

in PORPP. In the past year,

he continued his work with

Drs. Andy Stergachis and

Joseph Babigumira in the

Global Medicines Program to

support a human resources

intervention to strengthen the

supply chain of essential medicines in Malawi, and published

a methods manuscript describing an impact evaluation of

this project. He also worked with Dr. Brian Custer (Blood

Systems Research Institute) to develop a model to estimate

the cost-effectiveness and budget impact of Methylene Blue

Treated Plasma compared to the Quarantine Plasma for

pathogen reduction in Spain. Having successfully submitted

his short proposal, he is actively preparing for his general

examination. Solomon’s dissertation will explore the

economic and behavioral psychological factors affecting an

individual’s decision to take up medical male circumcision for

HIV prevention in Uganda.

Marita Mann, MPH, PhD Candidate

Marita Mann has completed her

third year in the PhD program.

Marita’s dissertation focuses

on the feasibility of a national

active surveillance system for

HIV medication in Namibia. She

has completed two technical

reports for the Ministry of

Health and Social Services in

Namibia which will lead to dissertation manuscripts. She also

presented this work at two scientific conferences. In addition,

Marita continues to work on the cost-effectiveness of cervical

cancer screening in Kenya, and presented that work at the

Conference for Retroviruses and Opportunistic Infections.

Marita has also begun working on device landscape analyses

with Boston Scientific, and will continue that and her

dissertation work throughout the coming year.



Cara McDermott, PharmD, MS, PhD Candidate

Cara passed her general exam

in December 2014 and is

working with SEER-Medicare

data for her dissertation,

entitled “Depression, Health

Care Utilization, Outcomes

and Costs among Lung Cancer

Patients.” She presented her

capstone project for the Graduate Certificate in Comparative

Effectiveness Research at the 2014 annual meeting of the

Society for Medical Decision Making in a poster presentation

entitled “Systematic Review and Meta-analysis of Directly

Observed Therapy for Treatment of Hepatitis C”. The poster

was a finalist for the Lee B. Lusted Student Prize. Cara

spent the past academic year as a teaching assistant for the

Certificate in Health Economics and Outcomes Research

distance learning program, a role she will continue in this

upcoming year.

Vanessa Shih, PharmD, MS, Allergan Post-Doctoral Fellow 2014-2016

Vanessa has finished the first

year of her fellowship and is

excited to spend the next year

on-site at Allergan in Irvine,

CA. Over the past year she has

been taking coursework and

working on her master’s thesis

titled “Assessing the burden of worsening self-reported

vision in older Americans using the Health and Retirement

Study.” Additionally, she presented a poster at the ISPOR

20th Annual International meeting titled “Estimating the cost-

effectiveness of left atrial appendage closure compared to

warfarin for stroke prevention in atrial fibrillation.” She will

be working with the Global Health Economics and Outcomes

Research team at Allergan in the eye care therapeutic area

and is looking forward to further developing her skill set in

outcomes research.

Kangho Suh, PharmD, MS

Kangho is entering his second

year in the PhD program is

PORPP. In the past year he was

the TA for pharmacy students

in the course Introduction

to Pharmacoeconomics and

Outcomes Research, taught by

Ryan Hansen. In the summer

he worked as a RA with Ryan

on cost-effectiveness projects

relating to multiple sclerosis treatments and therapy

interventions for veterans. He also worked as a RA with

Lou Garrison and Josh Carlson on a project funded by the

Corporate Advisory Board assessing the value of cures. He

will continue serving as the RA for the cures project for the

upcoming academic year.

Elisabeth Vodicka, MPH

Elisabeth will be a third year

PhD student in PORPP. Last

year, she was an RA for Brian

Bresnahan on a Gates-funded

economic evaluation of

portable ultrasound in low-

income countries, which she

will continue this year. She

also completed data collection

and analysis of cervical cancer

screening costs in Kenya, under the mentorship of Joseph

Babigumira and Lou Garrison, and published a paper with

Beth Devine and Donald Patrick on the use of patient-


reported outcomes in clinical trials. In early Fall, she will

travel to Peru to conduct qualitative research evaluating

patient preferences for using pharmacies for hypertension

prevention and management, under the guidance of

Andy Stergachis. She is refining her short proposal for her

dissertation on policies of cervical cancer screening in low-

resource settings.

Kai Yeung, PharmD, MS, PhD Candidate

Kai Yeung has completed his

fourth year in the PhD program.

During this academic year,

Kai has worked towards the

completion of his dissertation.

Kai’s dissertation focuses on

the evaluation of the impact of

a novel value-based formulary

which uses cost-effectiveness

analysis to determine drug copayments. Related to this work,

Kai gave a podium presentation on the “Application of Cost-

Effectiveness Logic to US Managed Care Drug Formularies:

Long Term Outcomes of a Value-Based Formulary” at the

20th annual international meeting of the International Society

for Pharmacoeconomics and Outcomes Research. This

presentation received ISPOR’s best student podium research

presentation award. He delivered another oral presentation

for a continuing pharmacy education session at the 27th

Annual Meeting of the Academy for Managed Care Pharmacy

entitled “Pharmacoeconomic Modeling: Applying Value to

Formulary Management”. Additionally, this year Kai has been

awarded an AHRQ Health Services Research Dissertation

grant which provides funding for the completion of his

dissertation research. Regarding professional service, Kai has

been selected to serve on the editorial advisory board for

the Journal of Managed Care & Specialty Pharmacy. Finally,

he served as a guest speaker for 2 UW courses for PharmD

students. Kai is very grateful to his mentors at PORPP for

their advisement.

Justin Yu, PharmD, MS UW/Bayer Post-Doctoral Fellow 2014-2016

Justin Yu is beginning the

2nd year of his post-doctoral

fellowship with the University

of Washington and Bayer. Prior

to the fellowship, he received

his PharmD from the University

of Southern California, where

he was active in student organizations for the pharmaceutical

industry and managed care. As a pharmacy student, he also

worked as an intern in both health-system and ambulatory

care settings – the latter which he credits for first sparking

his interest in HEOR. Following pharmacy school, Justin

spent one year at the University of Washington, where he

worked towards his Master’s degree in health economics

and outcomes research. Notable projects he worked on

included a cost-effectiveness analysis of idelalisib for relapsed

chronic lymphocytic leukemia and a systematic review of the

absenteeism costs of cancer. Both projects were presented as

posters at ISPOR 2015 and are currently being prepared for

publication. Additionally, Justin has also researched utility values

for non-Hodgkin’s lymphoma, which he aims to present at a

future conference and later publish. Lastly, Justin is currently

working on his thesis, which is titled “The Indirect Costs

and Outcomes Associated with Non-Hodgkin’s Lymphoma”

and involves the use of MarketScan Health Productivity &

Management data. Justin is excited to be at Bayer for the 2nd

year of his fellowship and looks forward to collaborating and

getting to know everyone on the HEOR team.


STUDENTS Continued



Jean McDougall, PhD, MPH

Jean is conducting a study of

determinants of adherence to

and elasticity of demand for

tyrosine kinase inhibitors as

part of her PhRMA Foundation

Health Outcomes Fellowship.

She is working with her

mentors Sean Sullivan and Scott

Ramsey on a variety of cancer

economics and outcomes projects, including an analysis

of the costs, resource utilization, and impact on survival of

skeletal related events among men with prostate cancer,

the results of which were presented at the American Society

of Clinical Oncology (ASCO) Genitourinary Symposium in

February and the ASCO Annual Meeting in May. In the last

year of her fellowship, Jean is writing a career development

award with the goal of developing an independent research

program addressing socioeconomic disparities in the

application of personalized medicine.

Souvik Banerjee

Souvik has recently commenced

his second year in the Pfizer post-

doctoral fellowship program

at PORPP. Over the course of

the past year, he has worked

closely with Lou Garrison on a

number of projects and has also

collaborated with researchers

at the Group Health Research

Institute in Seattle. Souvik’s

doctoral dissertation chapter, “Effects of Psychiatric Disorders

on Labor Market Outcomes: A Latent Variable Approach Using

Multiple Clinical Indicators” was presented at the Society of

Labor Economists 4th World Meeting in Montreal by one of his

co-authors and has been conditionally accepted for publication

in Health Economics. He has also worked on a study that sought

to estimate the cost-effective device prices for pediatric

cochlear implants in India and this work was presented at the

ISPOR 20th Annual Meeting in Philadelphia, 2015. During the

summer of 2015, Souvik spent close to 8 weeks in New York

City at Pfizer, Inc., working primarily with Dick Willke and will

continue with the existing projects in 2015-2016.


POST-DOCTORAL FELLOWS

The PORPP Endowed Prize was given to two students this year. Both Mark Bounthavong and Vanessa Shih had winning papers and they each received $500. The title of Mark’s paper was: “A Cost-Utility Analysis of Biologics for Moderate-to-Severe Crohn’s Disease: Evidence Synthesis Using Bayesian Network Meta-Analysis”. Vanessa’s paper was titled: “Estimating the Cost-Effectiveness of Left Atrial Appendage Closure with the Watchman® Device versus Dose-Adjusted Warfarin for Stroke Prevention in Atrial Fibrillation”.

The $1,000 Prize is awarded to eligible candidates in the PhD or Master’s program in PORPP, or related fields such as Public Health Genetics, Health Services, Economics or Global Health who are enrolled in a class taught by a PORPP faculty member. The paper must deal with an original health policy or health economic issue.

PORPP ENDOWED PRIZE RECIPIENTS 2015



The University of Washington ISPOR Student Chapter

exploded with new activity in the 2014-2015 academic year.

Under the direction of faculty advisor Professor Lou Garrison

and leadership of student co-presidents Marita Mann and Kai

Yeung, the UW ISPOR student chapter blossomed and held

more events than ever before.

Following a productive student breakout discussion on

mentoring at the previous spring retreat, the ISPOR student

chapter created a new peer-mentoring program. In Fall 2014,

new PhD students were assigned a volunteer peer-mentor a

few years advanced in the PhD program. The matches were a

huge success and provided support for new students in areas

such as navigating conferences for abstract submission and

when to form study groups to prepare for preliminary exams.

The UW ISPOR student chapter welcomed Fall quarter 2014

by hosting very popular catered networking lunches after

each weekly PORPP graduate seminar. An ISPOR Student

Chapter Grant supported the activity and it successfully

connected students to each other and faculty.

In the winter, ISPOR Student Chapter funds supported

travel for four students to present at the Western

Pharmacoeconomics and Outcomes Research Conference

in Denver, CO. It was a valuable opportunity to meet

PhD students and faculty from other programs and

practice presentation skills. While at the conference,

Mark Bounthavong received the award for best podium

presentation.

Throughout spring quarter, the chapter engaged students

of all stages by planning and hosting the weekly graduate

seminar with a focus on professional development. With

support from Professor Josh Carlson, the officers planned

11 seminars and invited guest speakers for sessions on

entrepreneurship, management, and strengthening our

resumes. Student Chapter Officers Mark Bouthavong and

Meng Li dedicated months planning content for the May

2015 PORPP Spring Retreat. Their efforts found the perfect

balance of valuable presentations, engaging student-faculty

discussions, and fun team-bonding activities.

As student chapter president, Marita Mann served on a

planning committee for ISPOR and participated in monthly

conference calls with other chapter presidents. Three PORPP

students attended the ISPOR Student Presidents Retreat in

Philadelphia. The retreat was an excellent opportunity to

learn what other PhD programs have accomplished through

their ISPOR student chapters.


GROWTH OF THE UW ISPOR STUDENT CHAPTER

BY BLYTHE ADAMSON


“As vice-president of the ISPOR student chapter at UW, I was

able to observe our co-presidents’ leadership skills and vision.

Their vision was to expand the influence of the ISPOR student

chapter and to continue collaboration across different

departments. I hope to continue this mission as well as

expand our network to beyond the Pharmacy School.”

– Mark Bounthavong, Vice-President of the ISPOR Student

Chapter

In the upcoming 2015-2016 academic year, the new ISPOR

Student Chapter Officers are excited to participate in

planning 20th anniversary events such as the research

symposium and special edition spring PORPP retreat.

In addition to continuing all the new chapter activities,

the student chapter plans to grow the peer-mentoring

program by building on mentorship of local high school

students that some PORPP PhD students have already

started. Our PORPP graduate students and ISPOR

Student Chapter members have been invited to lecture

and mentor students at Lakeside High School, Fairview

Christian School, Nathan Hale High School, and Roosevelt

High School. We also look forward to a joint effort with

UW Health Services PhD Student Jeremy Snider, student

chapter president for Academy Health, to plan a screening

of the movie “PhD” about the life of a graduate student.

2014-2015 OFFICERS

President: Marita Mann

Co-President: Kai Yeung

Vice-President: Mark Bounthavong

Treasurer: Meng Li

2015-2016 OFFICERS

President: Mark Bounthavong

Vice-president: Blythe Adamson

Secretary: Elisabeth Vodicka

Treasurer: Meng Li

ADVANCED METHODS:

Advanced Methods is exactly what you would expect it to

be—a series dedicated to the promotion and application

of advanced methods in epidemiology and economics.

The large amount of material that gets compressed into

three quarters provides a firm foundation on topics such as

two-part models, generalized linear models, and multiple

imputation for missing data. It also exposes students

to progressive methods such as extended estimating

equations and instrumental variables. All these tools

allows the student to mitigate bias and establish significant

associations and, in some cases, causal inference. More

importantly, this series imbues students with a sense

of responsibility to use these tools appropriately and to

become the future custodians of scientific integrity.



The AHRQ-funded Health Services Research Training (HSRT)

Program at the University of Washington in the Department

of Health Services and the School of Pharmacy prepares

research leaders to improve health in diverse populations by

conducting interdisciplinary studies and implementing the

results in a rapidly changing health care and social-political

environment. The program builds capacity in health services

research nationally and in the Pacific Northwest region,

serving 5 states with 27% of the U.S. land mass.

Trainees include six predoctoral students in the Department

of Health Services and two predoctoral students in the

Pharmaceutical Outcomes Research & Policy Doctoral

Program (PORPP), who also will obtain a university-wide

Certificate in CER. We recruit highly qualified trainees

from different backgrounds who have the potential for an

outstanding career in health services research.

The competency-based curriculum provides: 1)

comprehensive knowledge of the health care system, health

policy and the determinants/disparities of population health;

2) rigorous training in the theory and research methods of

key disciplines; 3) expertise in an area of emphasis through

intensive preparation in theory, content, and methods; and 4)

training in effective communication within organizations and

with scientfic and lay audiences. Trainees carry out applied,

multidisciplinary research at external research partners

and UW centers. Strong mentorship produces high quality

research aligned with AHRQ priorities and facilitates the

translation of findings into policy and practice.

GRADUATE TRAINING

AHRQ T32


This program aims to develop early career scientists in

Patient Centered Outcomes Research, evidence development,

adoption and evaluation. At the completion of their training,

Scholars will have cutting edge Patient Centered Outcomes

Research skills and a grounding in implementation and

dissemination science. Our overall aims are to (1) provide

Scholars with multidisciplinary training, (2) activate Scholars

to utilize existing and unparalleled opportunities within the

UW and affiliated institutions to learn PCOR and CER from

experts with ongoing projects, multidisciplinary teams, data

resources, and real world populations and stakeholders,

(3) create an environment that supports the early research

efforts of junior faculty, infuses them with the excitement of

comparative effectiveness research and nurtures their early

career development and productivity and aids in ensuring a

long term career in conducting and teaching PCOR.

AHRQ PCOR K12

“There is no doubt that my research experience at

PORPP has been invaluable to my career. But, I equally

value the memories of fun times and lifelong friendships

forged during my training. When I meet new PORPP

students and faculty, I’m delighted to see that the

camaraderie continues.”

Shelby Reed, PhD (Post-Doctoral Fellowship 2000)


FACULTY AWARDSAasthaa Bansal, Best Podium by New Investigator at the ISPOR Annual International Meeting, Philadelphia, 2015

Aasthaa Bansal, Research Starter Grant in Health Outcomes, PhRMA Foundation, 2015

Bernardo Goulart, New Investigator Award from the Cancer Center Support Grant, UW & Fred Hutchinson Cancer Consortium

Josh Roth, New Investigator Research Presentation Podium Award, ISPOR, 2015

Josh Roth, 2015 ISPOR Award for Research Excellence in Application of Pharmacoeconomics and Health Outcomes for paper, “Economic Return From the Women’s Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study” Ann Intern Med 2014;160:594-602

Gary Lyman, Newsweek, “Top Cancer Doctors in America”

Sean Sullivan, Research Achievement Award in the Pharmaceutical Sciences, from The American Pharmacists Association (APhA)

STUDENT AWARDSBlythe Adamson, Center for AIDS Research (CFAR) Trainee Grant, 2015

Blythe Adamson, Scholarship Award for the Summer Institute in Statistics and Mathematical Modeling of Infectious Diseases, 2015

Mark Bounthavong, Best Podium presentation at the Western Pharmacoeconomics and Outcomes Research Conference, Denver, CO

William Canestaro, AFPE Pre-doctoral Grant

William Canestaro, PhRMA Foundation 2015 Pre-Doctoral Fellowship

Meng Li, Best Poster Finalist at ISPOR International Annual Meeting, Philadelphia, 2015

Jean Malacan, Very Honorable Distinction for Pharmacy Thesis and nomination for the Annual Pharmacy School Award, Paris Sud University

Cara McDermott, Society for Medical Decision Making Lee B. Lusted Prize Finalist, 2014 Annual Meeting

Elisabeth Vodicka, Recipient of Stergachis Endowed Fellowship for International Exchange

Kai Yeung, Best Podium by student at the 2015 ISPOR Annual International Meeting (second year in a row!)

Kai Yeung, Agency for Healthcare Research and Quality Health Services Research Dissertation Grant

REDUCING BARRIERS FOR THE AMBITIOUS SCHOLARSHIP, ESTABLISHED BY ALUMNUS DR. DANA HURLEY

Blythe Adamson, Mark Bouthavong, Marita Mann, Solomon Lubinga, Meng Li

PORPP AWARD FOR BEST GRADUATE STUDENT PAPER 2014-2015:

Mark Bounthavong, Vanessa Shih

ALUMNI AWARDS

Julia Slejko (our last Pfizer post-doc, for work was based on

the PORPP Heath-Tech Fund project), Best Poster by New

Investigator at the 2015 ISPOR Annual International Meeting

Chris Wallick (alumnus and previous Allergan fellow), Best

Poster at the 2015 ISPOR Annual International Meeting.

AWARDS 2014–15


Anirban Basu, Associate Editor, Health Economics

Anirban Basu, Associate Editor, Journal of Health Economics

Amy Cizik, UW Graduate & Professional Student Senate Childcare Advisory Committee

Beth Devine, Board Member, Advisory Panel of the Research & Education Foundation of the American Society of Health-System Pharmacists

Beth Devine, Senior Editor, eGEMS, Generating Evidence & Methods to improve patient outcomes, AcademyHealth

Lou Garrison, International Meeting Program Co-Chair and President-elect (2016-2017) of the International Society for Pharmacoeconomics &Outcomes Research (ISPOR)

Shelly Gray, Editorial Board Member, American Geriatrics Society

Shelly Gray, Board Member, Safe Driving Program for Older Adults

Lotte Steuten, Board Member, Scientific Advisory Board of the Global Initiative for Translational Health Economics (GITHE)

Lotte Steuten, Editorial Board Member, OMICS: A Journal of Integrative Biology

Lotte Steuten, Editorial Board Member, Applied Health Economics & Health Policy Journal

Dave Veenstra, Co-Editor, Value in Health

Elisabeth Vodicka, Member of Students of Public Health Engaged in Reproductive Rights Efforts

Kai Yeung, Editorial advisory board for the Journal of Managed Care & Specialty Pharmacy

ISPOR STUDENT CHAPTER OFFICERS 2014-2015

Marita Mann, President

Kai Yeung, Co-President

Mark Bounthavong, Vice President

Meng Li, Secretary

Professor Lou Garrison, Faculty Advisor

SERVICE


Canestaro WJ, Edwards TC, Patrick DL. Systematic Review of the Patterns of Use Characteristics and Quality of Patient Reported Outcome Measures in Celiac Disease. ISPOR 20th Annual International Meeting May 16-20, 2015. Philadelphia, PA, USA.

Garland T, Cizik AM, Jones R, Davidson D: “Outcomes of Leiomyosarcoma of Bone: A Comparative Study with Other Primary Bone Sarcomas.” Presented as a poster at the annual meeting of the Connective Tissue Oncology Society, Berlin, Germany, October 2014.

Keyloun KR, Devine EB. Estimating the Cost-Effectiveness of Vortioxetine versus Desvenlafaxine as first line Therapy for mild to moderate Major Depressive Disorder in Remitted Patients. Poster Presentation at the International Society of Pharmacoeconomics and Outcomes Research International Meeting. May 2014; Philadelphia, PA.

Kim RD, et al. Variations in Treatment of Non-Tuberculous Mycobacteria Infection in the United States, 2007-2013. American Thoracic Society International Conference, 2015.

Li M, Babigumira J, Boudreau D, Garrison L. Comparing Alternative Econometric Models for Estimating Healthcare Expenditures. Western Pharmacoeconomics and Outcomes Research Conference, March 5, 2015, Denver, Colorado, United States

Lubinga, S. A Cost Effectiveness Analysis of Antipsychotics for the Treatment of Schizophrenia in Uganda, ISPOR International Annual Meeting; Philladelphia, May 2015 (poster).

Lubinga, S. A budget impact analysis of the use of Methylene Blue Treated Plasma compared to Quarantine Plasma for Pathogen Reduction. AABB; Spain, 2015 (poster).

Mann M, Adamson B, Stergachis, A. “A Framework for Strengthening Pharmaceutical Manufacturing in Sub-Saharan Africa” Western Pharmacoeconomics and Outcomes Research Conference, Poster Presentation, Philadelphia (2015)

McDermott CL, Lockhart C, Devine EB. Systematic review and meta-analysis of directly observed therapy for treatment of hepatitis C. 2014 Annual Meeting of the Society for Medical Decision Making. Miami FL, (poster)

Ozawa, S., Clark, S., Grewal, S., Stack, M.L., Sinha, A., Mirelman, A., Franklin, H., Portnoy, A., Hansen, P., Johnson, H., & Walker, D. Estimated health and economic impact of immunization programs across 73 countries and ten antigens, 2001-2020. Poster presented at the Society of Medical Decision Making Conference; Miami, FL; October 2014 (poster)

Shih V, Devine B. Estimating the cost-effectiveness of left atrial appendage closure compared to warfarin for stroke prevention in atrial fibrillation. ISPOR 20th Annual International Meeting. May 16-20, 2015. Philadelphia, PA.

Vodicka E, Babigumira JB, Mann M, Kosgei RJ, Lee F, Mugo N, Okech T, Sakr S, Garrison LP, Chung MH. Costs of Cervical Cancer Screening Methods Integrated into HIV Care in Nairobi, Kenya. Poster session presented at: International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention; June 21, 2015; Vancouver, BC.

STUDENT POSTERSAdamson B, Bouthavong M, Kublin J, Garrison L. “Cost-Effectiveness Analysis of a Partially Effective HIV Vaccine in San Francisco.” International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting, Poster Presentation; Philadelphia, CO, 2015.

Adamson B, Bouthavong M, Kublin J, Garrison L. “Economic Evaluation of a Partially Effective HIV Vaccine in San Francisco.” Western Pharmacoeconomics and Outcomes Research Conference; Poster Presentation, Denver, CO, 2015.

Babigumira J, Li M, Boudreau D, Best J, Garrison L. Estimating the Cost of Illness of Giant Cell Arteritis. ISPOR 20th Annual International Meeting, May 19, 2015, Philadelphia, Pennsylvania, United States.

Bennette C, Basu A, Ramsey S, Veenstra D, Carlson J. Incorporating Stakeholder Preferences into the Development and Presentation of Value of Information (VOI) Analysis to Inform Real-World Research Investment Decisions in a US Cancer Clinical Trials Group. Society for Medical Decision Making. Miami, FL, October 2014.

Bounthavong M, Li M, Watanabe JH. An evaluation of health care expenditures in Crohn’s disease from 2003 to 2012 using the US Medical Expenditure Panel Survey. Presented at the 21st Annual National Research Services Award (NRSA) Conference, Minneapolis, Minnesota ( June 13, 2015).

Bounthavong M, Bae Y, Vanness DJ, Kazerooni R, Devine EB. An evaluation of clinical remission and safety among biologics for moderate-to-severe Crohn’s disease: A Bayesian network meta-analysis. Presented at the 20th Annual International Society for Pharmacoeconomics and Outcomes Research Meeting. Philadelphia, PA (May 16-20, 2015).

Bounthavong M, Bae Y, Devine EB, Veenstra D. A cost-utility analysis of biologics for moderate-to-severe Crohn’s disease: Evidence synthesis using a Bayesian network meta-analysis. Presented at the 20th Annual International Society for Pharmacoeconomics and Outcomes Research Meeting. Philadelphia, PA (May 16-20, 2015).

Canestaro WJ, Vodicka E, Downing D. Implications of Employer Coverage of Contraception: Cost-Effectiveness of Contraception Under an Employer Mandate. Poster session presented at: International Society for Pharmacoeconomics & Outcomes Research Annual Meeting; May 18, 2015; Philadelphia, PA.

Canestaro WJ, Regier DA, Veenstra DL, Lavallee D, Basu A, Carlson JJ. Factors Impacting Personalized Medicine Test Adoption: Evaluating Patient Preferences and Willingness to Pay. ISPOR 20th Annual International Meeting May 16-20, 2015. Philadelphia, PA, USA.

Canestaro WJ, Forrester S, Ho L, Devine B. Drug Therapy for Treatment of Idiopathic Pulmonary Fibrosis: A systematic Review and Network Meta-Analysis. ISPOR 20th Annual International Meeting May 16-20, 2015. Philadelphia, PA, USA.

STUDENT PUBLICATIONS & PRESENTATIONSStudent and Faculty names are highlighted in bold



Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of Patient-Reported Outcome Measures in Registered Clinical Trials: Evidence from ClinicalTrials.gov (2007-2013). Poster session presented at: International Society for Pharmacoeconomics & Outcomes Research Annual Meeting; May 19, 2015; Philadelphia, PA.

Watanabe JH, Singh R, Morello C, Bounthavong M, Hirsch JD. Are Medicare and Medicare-Medicaid insulin users different? Comparisons in a nationally representative claims database. Presented at the 75th Scientific Session for the American Diabetes Association, Boston, MA ( June 5-9, 2015).

Wu X, Shi Q, Huang Y, Yin H, Li M, Patel S, Wu Y. Budget Impact Model of Sunitinib As First Line Treatment of Metastatic Renal Cell Carcinoma In China. ISPOR 6th Asia-Pacific Conference, September 7, 2014, Beijing, China.

STUDENT ORAL PRESENTATIONSBounthavong M, Bae Y, Devine EB, Veenstra D. A cost-utility analysis of biologics for moderate-to-severe Crohn’s disease: Evidence synthesis using a Bayesian network analysis. Western Pharmacoeconomics and Outcomes Research Conference. Aurora, CO, March 5-6, 2015.

Cizik AM. The Basis for Clinical Decision Making in Orthopaedics – Session III: Basic and Definitions. Presented at the annual meeting of the Orthopaedic Research Society, Las Vegas, NV, March 2015.

Simianu V, Cizik AM, Flum DR, Mann GN, Davidson DJ: “A Discrete Choice Experiment Reveals Physician Bias in Management of Desmoid Tumors.” Presented by V. Simianu at the annual meeting of the Connective Tissue Oncology Society, Berlin, Germany, October 2014.

Ozawa S, Grewal S, and Bridges J. Examining the impact of household size on community-based health insurance preferences in Cambodia: Results from a scale-adjusted discrete choice experiment. Oral presentation at the International Health Economics Association Congress. Milan, Italy; July 2015.

Li M, Dick A, Montenovo M, Horslen S, Hansen R. Cost-effectiveness of Liver Transplantation in Methylmalonic and Propionic Acidemias. Liver Transpl. 2015 May 19. [Epub ahead of print]

Bresnahan B and Vodicka E. Economic Strategy for Assessing Ultrasound Use To Improve Pregnancy Outcomes In Lower-Income Country Settings: Outcomes of a Cluster Randomized Trial. Co-Presentation at Global Network Meeting. June 22, 2015; Washington, DC.

Yeung, K. Application of Cost-Effectiveness Logic to US Managed Care Drug Formularies: Long Term Outcomes of a Value-Based Formulary. Oral presentation at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting. May 2015; Philadelphia, PA.

Yeung, K. Pharmacoeconomic Modeling: Applying Value to Formulary Management. Oral Presentation at the Academy of Managed Care Pharmacy’s 27th Annual Meeting and Expo. April 2015; San Diego, CA.

PUBLICATIONSAdamson B, Fuchs J, Sopher C, Flood D, Johnson RP, Haynes B, Kublin J. A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines. Clinical and Translational Science. 2015 Apr;8(2):166-8.

Gallego CJ, Bennette CS, Heagerty P, Comstock B, Horike-Pyne M, Hisama F, Amendola LM, Bennett RL, Dorschner MO, Tarczy-Hornoch P, Grady WM, Fullerton SM, Trinidad SB, Regier DA, Nickerson DA, Burke W, Patrick DL, Jarvik GP, Veenstra DL. Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemp Clin Trials. 2014 Sep;39(1):1-8.

Watanabe JH, Chen T, Bounthavong M, Hsu JC. Consideration of New Guidelines for Cholesterol Reduction: Comparison of Lipid Reduction Threshold Achievement by ACC/AHA Benefit Groups. International Library of Diabetes and Metabolism. 2015;1(1):13-16.

Bounthavong M, Watanabe JH, Sullivan K. Approach to addressing missing data for electronic medical records and pharmacy claims research. Pharmacotherapy. 2015 Apr;35(4):380-7. doi: 10.1002/phar.1569.

Kazerooni R, Nguyen JB, Bounthavong M, Tran MH, Madkour N. New start versus continuing users on aripiprazole: Implications for policy. Am J Manag Care. 2015;21(1):e43-e50.

Sakharkar P, Bounthavong M, Hirsch JD, Morello CM, Chen TC, Law AV. Development and validation of PSPSQ 2.0 measuring patient satisfaction with pharmacist services. Res Social Adm Pharm. 2014 Oct 22. pii: S1551-7411(14)00336-2. doi: 10.1016/j.sapharm.2014.10.006. PMID: 25481330.

Gundle KR, Cizik AM, Jones RL, Davidson DJ. Quality of life measures in soft tissue sarcoma. Expert Review of Cancer Therapy, 2015, Vol. 15(1), 95-100.

Gundle KR, Cizik AM, Punt SEW, Conrad III EU, Davidson DJ. Validation of the SF-6D Health State Utilities Measure in Lower Extremity Sarcoma. Sarcoma, 2014.Lee MJ, Cizik AM, Hamilton D, Chapman JR. Predicting surgical site infection after spine surgery: a validated model using a prospective surgical registry. Spine J, 2014, Vol. 14(9):2112-7.

Manoso MW, Cizik AM, Bransford RJ, Bellabarba C, Chapman J, Lee MJ. Medicaid status is associated with higher surgical site infection rates after spine surgery. Spine, 2014, Vol. 39(20): 1707-13.

Mirelman A.J, Ozawa S, & Grewal S. (2014). The economic and social benefits of childhood vaccinations in BRICS. Bull World Health Organ, 92(6), 454-456.

Portnoy A, Ozawa S, Grewal S, Norman BA, Rajgopal J, Gorham KM, ... & Lee BY (2015). Costs of vaccine programs across 94 low-and middle-income countries. Vaccine, 33, A99-A108.

Kim RD, Kapur VK, Redline-Bruch J, Rueschman M, Auckley DH, Benca RM, Foldvary-Schafer NR, Iber C, Zee PC, Rosen CL, Redline S, Ramsey SD. An Economic Evaluation of Home Versus Laboratory-Based Diagnosis of Obstructive Sleep Apnea. Sleep. 2015 Jul 1;38(7):1027-37. doi: 10.5665/sleep.4804.



JOSEPH BABIGUMIRALubinga SJ, Jenny AM, Larsen-Cooper E, Crawford J, Matemba C, Stergachis A, Babigumira JB, Impact of Pharmacy Worker Training and Deployment on Access to Essential Medicines and Health Outcomes in Malawi: Protocol for a Cluster Quasi-Experimental Evaluation. Implementation Science. Implement Sci. 2014 Oct 11;9:156.

Babigumira JB, Vlassoff M, Ahimbisibwe A, Stergachis A. Surgery for family planning, abortion, and postabortion care. In: World Bank: Disease Control Priorities 3rd edition (DCP3). World Bank Group. 2015. http://www.dcp-3.org/surgery

Verguet S, Olson ZD, Babigumira JB, Desalegn D, Johansson KA, Kruk ME, Levin CE, Nugent RA, Pecenka C, Shrime MG, Memirie ST, Watkins DA, Jamison DT. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. Lancet Glob Health. 2015 May;3(5):e288-96

AASTHAA BANSALSolorio R, Bansal A, Comstock B, Ulatowski K (2015). Impact of a chronic care coordinator intervention on diabetes quality of care in a community health center. Health Services Research, 50(3): 730-749.

Shiovitz S, Bansal A, Burnett-Hartman AN, Karnopp A, Adams SV, Korenbot C, Warren-Mears V, Ramsey S (2015). Cancer-directed therapy and hospice care for metastatic cancer in American Indians and Alaska Natives. Cancer Epidemiology, Biomarkers & Prevention, 24(7): 1138-1143.

Shankaran V, Mummy D, Kopel L, Bansal A, Mirich DK, Yu E, Morlock R, Ramsey SD (2014). Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. The Oncologist, 19(8): 892-899.

ANIRBAN BASUBasu A. Financing Cures in the United States. Expert Review of Pharmacoeconomics and Outcomes Research 2015; 15(1): 1-4.

Basu A. Welfare implications of learning through solicitation versus diversification in health care. NBER Working paper # 20367. Journal of Health Economics 2015; 42: 165-173.

Basu A, Gore J. Are elderly patients with clinically localized prostate cancer overtreated? Exploring heterogeneity in survival effects. Medical Care 2015; 53(1):79-96.

CARRIE BENNETTEGallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. J Clin Oncol. 2015 Jun 20;33(18):2084-91. doi: 10.1200/JCO.2014.59.3665. Epub 2015 May 4.

Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med. 2015 Jul 2;17(7):587-95. doi: 10.1038/gim.2014.156. Epub 2014 Nov 13.

Lubinga SJ, Jenny AM, Larsen-Cooper E, Crawford J, Matemba C, Stergachis A, Babigumira JB. Impact of pharmacy worker training and deployment on access to essential medicines and health outcomes in Malawi: protocol for a cluster quasi-experimental evaluation. Implement Sci. 2014 Oct 11;9:156

Lubinga SJ, Mutamba BB, Nganizi A, Babigumira JB. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. Appl Health Econ Health Policy. 2015 May 10. [Epub ahead of print]

Shih V, Ten Ham RM, Bui CT, Tran DN, Ting J, Wilson L. Target Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis. J Skin Cancer. 2015

Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of Patient-Reported Outcome Measures in Registered Clinical Trials: Evidence from ClinicalTrials.gov (2007-2013). Contemp Clin Trials. 2015 Apr 18; 43:1-9. doi: 10.1016/j.cct.2015.04.004.

Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015 Apr;21(4):269-75.

STUDENT PUBLICATIONS & PRESENTATIONS Continued

FACULTY PUBLICATIONS

“The PORPP PhD program and post-

doctoral fellowship provided an ideal

trajectory for an academic career in

pharmaceutical outcomes research.

Memories will not be forgotten of grad

office studies, trailer park shared office

space, raccoons, and dear friends.”

Jonathan D. Campbell, PhD, 2007



DENISE BOUDREAUBoudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL. Cost-Effectiveness of Recombinant Tissue Plasminogen Activator within 3 Hours of Acute Ischemic Stroke using Current Evidence. Stroke. 2014;45:3032-39.

Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014;144:405-16.

Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau DM*. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiol Drug Saf. 2015 Apr 8. [Epub ahead of print]

BRIAN BRESNAHANAndre JB, Bresnahan BW, Mossa-Basha M, Hoff MN, Smith CP, Anzai Y, Cohen WA.Toward Quantifying the Prevalence, Severity, and Cost Associated With Patient Motion During Clinical MR Examinations. J Am Coll Radiol. 2015 Jul;12(7):689-95. doi: 10.1016/j.jacr.2015.03.007. Epub 2015 May 9. PMID: 25963225

Jarvik JG, Gold LS, Comstock BA, Heagerty PJ, Rundell SD, Turner JA, Avins AL, Bauer Z, Bresnahan BW, Friedly JL, James K, Kessler L, Nedeljkovic SS, Nerenz DR, Shi X, Sullivan SD, Chan L, Schwalb JM, Deyo RAAssociation of early imaging for back pain with clinical outcomes in older adults.JAMA. 2015 Mar 17;313 (11):1143-53. doi: 0.1001/jama.2015.1871. Erratum in: JAMA. 2015 May 5;313(17):1758. PMID: 25781443

JOSH CARLSONCarlson JJ, Ogale S, Dejonckheere F, Sullivan SD. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Health. Mar 2015;18(2):173-179.

Campbell JD, McQueen RB, Libby AM, Spackman DE, Carlson JJ, Briggs A. Cost-effectiveness Uncertainty Analysis Methods: A Comparison of One-way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. Med Decis Making. Oct 27 2014.

Canestaro, W, Carlson JJ, Garrison, LP, Veenstra DL. Cost-Effectiveness, Economic Incentives, and Reimbursement Issues. Chapter 17. In Pharmacogenomics: Applications to Patient Care, 3rd Ed.. American College of Clinical Pharmacy.

EMILY BETH DEVINEVodicka E, Kim K, Devine EB, Gnanasakthy A, Patrick DL. The use of patient-reported outcome instruments in clinical trials. Contemp Clinical Trials, 2015;43:1-9. doi: 10.1016/j.cct.2015.04.004

Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA. The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015 Jan 13. doi: 10.7326/M14-2559

Hersh W, Totten A, Eden K, Devine B, Gorman P, Kassakian S, Woods S, Daeges M, Pappas M, McDonagh M. Health Information Exchange. Evidence Report/Technology Assessment No. ##. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. HHSA 290201200014I.) AHRQ Publication No. ##. Rockville, MD: Agency for Healthcare Research and Quality; April 2015. www.effectivehealthcare.ahrq.gov

LOUIS GARRISON, JR.Garrison LP, Carlson JJ, Bajaj PS, Towse A, Neumann PJ,, Sullivan SD, Westrick KD, Dubois RW. Private Sector Risk-Sharing Agreements in the U.S.: Trends, Barriers, and Prospects, Forthcoming AJMC.

Garrison LP, Babigumira JB, Masaquel A, Wang B, Lalla D, Brammer M. The lifetime economic burden of inaccurate HER2 testing: estimating the costs of false positive and false negative HER2 test results in US patients with early-stage breast cancer. Value in Health; 2015 Jun;18(4):541-6

Agapova M, Devine EB, Bresnahan BW, Higashi MK, Garrison LP Jr. Applying quantitative benefit-risk analysis to aid regulatory decision making in diagnostic imaging: methods, challenges, and opportunities. Acad Radiol. 2014 Sep;21(9):1138-43.

BERNARDO GOULART Roth JA, Sullivan SD, Goulart BH, Ravelo A, Sanderson JC, Ramsey SD. Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare. Journal of Oncology Practice. 2015 Jus;11(4):267-272.

Goulart, B. Lung cancer CT screening is cost-effective but implementation matters. Evidence Based Medicine. 2015 Apr;20(2):78.

Goulart BH The Value of Lung Cancer CT Screening: It Is All about Implementation. American Society of Clinical Oncology Educational Book. 205;35:e426-433.

SHELLY GRAYDublin S, Walker RL, Gray SL, Hubbard R, Anderson ML, Yu O, Crane PK, Larson EB. Prescription opioids and risk of dementia or cognitive decline J Am Geriatr Soc 2015 In press

Gray SL, Anderson ML, Dublin S, Hanlon JT, Walker RL, Hubbard R, Yu O, Crane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia JAMA Intern Med 2015 175(3):401-407. doi: 10.1001/jamainternmed.2014.7663 [Epub ahead of print] NIHMS 665195

Lo-Ciganic WH, Perera S, Gray SL, Boudreau R, Zgibor JC, Strotmeyer E, Donohue JM, Bunker CH, Newman AB, Simonsick E, Bauer DC, Satterfield S, Caserotti P, Harris T, Shorr RI, Hanlon JT for the Health ABC Study. Statin Use and Gait-Speed Decline in Community-Dwelling Older Adults: Results from the Health, Aging and Body Composition Study J Am Geriatr Soc 2015;63:124-9. doi: 10.1111/jgs.13134. Epub 2014 Dec 23.




JEANNINE MCCUNEOverby CL, Devine EB, Abernethy N, McCune JS, Tarczy-Hornoch P. Making Pharmacogenomic-based Prescribing Alerts More Effective: A Scenario-based Pilot Study with Physicians. Journal of Biomedical Informatics, J Biomed Inform. 2015 Jun;55:249-59. doi: 10.1016/j.jbi.2015.04.011. Epub 2015 May 7. PMID: 25957826.

McCune JS, Jacobson PJ, Wiseman A, Militano O. Optimizing Drug Therapy in Pediatric Stem Cell

Transplantation: Focus on Pharmacokinetics. Bone Marrow Transplant. 2015 Feb;50(2):165-172. PMID: 25347008.

Bemer MJ, Risler LR, Phillips BR, Wang J, Storer BE, Sandmaier BM, Duan H, Raccor BS, Boeckh MJ, McCune JS. Recipient inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2014 Oct;20(10):1544-52. doi: 10.1016/j.bbmt.2014.05.032. Epub 2014 Jun 9. PMID: 24923537

SCOTT RAMSEY Ramsey SD, Fedorenko C, Chauhan R, McGee R, Lyman GH, Kreizenbeck K, Bansal A. Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer. J Oncol Pract. 2015. Epub 2015/06/11. doi: 10.1200/jop.2014.002717. PubMed PMID: 26060225.

Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol. 2015;33(2):149-55. Epub 2014/10/22. doi: 10.1200/jco.2014.55.5409. PubMed PMID: 25332254; PMCID: Pmc4279234.

Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, Briggs A, Sullivan SD. Cost-Effectiveness Analysis Alongside Clinical Trials II-An ISPOR Good Research Practices Task Force Report. Value Health. 2015;18(2):161-72. Epub 2015/03/17. doi: 10.1016/j.jval.2015.02.001. PubMed PMID: 25773551.

JOSHUA ROTHRoth, JA, Sullivan SD, Goulart BHL, Ravelo A, Sanderson JC, Ramsey SD. 2015. Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare.. Journal of oncology practice / American Society of Clinical Oncology. 11(4):267-72.

Roth, JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D. 2015. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.. Pharmacoepidemiology and drug safety

Wang, B, Roth JA, Nguyen H, Felber E, Furnback W, Garrison LP. 2015. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.. PloS one. 10(4):e0121915.

RYAN HANSENHansen RN, Boudreau DM, Ebel BE, Grossman DC, Sullivan SD. Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash. American Journal of Public Health. In Press, April 15, 2015.

Chou R, Deyo R, Devine B, Hansen RN, Sullivan S, Jarvik JG, Blazina I, Dana T, Bougatsos C, Turner J. The Effectiveness and Risks of Long-term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine. 2015;162(4):276-86

Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Healthcare Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib. Journal of Managed Care and Specialty Pharmacy. 2015;21(1):37-44

JERRY JARVIK Jarvik JG, Gold LS, Comstock BA, Heagerty PJ, Rundell SD, Turner JA, Avins AL, Bauer Z, Bresnahan BW, Friedly JL, James K, Kessler L, Nedeljkovic SS, Nerenz DR, Shi X, Sullivan SD, Chan L, Schwalb JM, Deyo RA. Association of early imaging for back pain with clinical outcomes in older adults. JAMA, Mar 17;313(11):1143-53, 2105. PMID:25781443

Deyo RA1, Bryan M, Comstock BA, Turner JA, Heagerty P, Friedly J, Avins AL, Nedeljkovic SS, Nerenz DR, Jarvik JG. Trajectories of Symptoms and Function in Older Adults with Low Back Disorders Spine (Phila Pa 1976). 2015 May 20. [Epub ahead of print]

Turner JA1, Comstock BA2, Standaert C3, Heagerty PJ2, Jarvik JG4, Deyo RA5, Wasan AD6, Nedeljkovic SS7, Friedly JL3. Can Patient Characteristics Predict Benefit from Epidural Corticosteroid Injections for Lumbar Spinal Stenosis Symptoms? Spine J. 2015 Jun 18. [Epub ahead of print]

GARY LYMANDinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncol. 2015 May 1;1(2):158-66.

Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Jun 22. [Epub ahead of print]

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20;33(6):654-6. Epub 2015 Jan 20.




ANDY STERGACHISNwokike J, Kabore L, Stergachis A. Actions of the national regulatory authorities in 10 low- and middle-income countries following stringent regulatory authority safety alerts on rosiglitazone. Therapeutic Innovation & Regulatory Science. 2015;49:279-283.

Kovacs SD, Rijken M, Stergachis A. Treating severe malaria in pregnancy: a review of the evidence. Drug Safety. 2015;38:165-81.

Wagenaar BH, Stergachis A, Hoek R, Cumbe V, Rao D, Napúa M, Sherr K. The availability of essential medicines for mental healthcare in Sofala, Mozambique. Global Health Action. 2015 Jun 15;8:27942.

LOTTE STEUTENMiquel-Cases A, Steuten LM, Retèl VP, van Harten WH. Early stagecost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy. Breast. 2015 Aug;24(4):397-405. doi: 10.1016/j.breast.2015.03.002. Epub 2015 Apr 28. PubMed PMID: 25937263.

Deeg HJ, Steuten LM. Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics: Difficult Decisions. JAMA Oncol. 2015 Jun 11. doi: 10.1001/jamaoncol.2015.1084. [Epub ahead of print] PubMed PMID: 26181003.

Mewes JC, Steuten LM, Duijts SF, Oldenburg HS, van Beurden M, Stuiver MM, Hunter MS, Kieffer JM, van Harten WH, Aaronson NK. Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. J Cancer Surviv. 2015 Mar;9(1):126-35. doi: 10.1007/s11764-014-0396-9. Epub 2014 Sep 2. PubMed PMID: 25179578

SEAN SULLIVAN Sullivan SD, Yeung K, Vogeler C, et al. Design, implementation, and first-year outcomes of a value-based drug formulary. Journal of Managed Care and Specialty Pharmacy 2015 Apr;21(4):269-75

Pauly MV, Sloan FA, Sullivan SD. An economic framework for preventive care advice. Health Affairs 2014 33(11):2034-2040.

Roth JA, Sullivan SD, Goulart B, Ravelo A, Sanderson JC, Ramsey SD. Projected clinical, resource use and fiscal impact of implementing low-dose computed tomography lung cancer screening in Medicare. Journal of Oncology Practice 2015 Jul;11(4):267-72.

DAVID VEENSTRA Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. J Clin Oncol. 2015 Jun 20;33(18):2084-91. doi: 10.1200/JCO.2014.59.3665. Epub 2015 May 4. PMID: 25940718

Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med. 2015 Jul 2;17(7):587-95. doi: 10.1038/gim.2014.156. Epub 2014 Nov 13. PMID: 25394171 Free PMC Article

Gallego CJ, Bennette CS, Heagerty P, Comstock B, Horike-Pyne M, Hisama F, Amendola LM, Bennett RL, Dorschner MO, Tarczy-Hornoch P, Grady WM, Fullerton SM, Trinidad SB, Regier DA, Nickerson DA, Burke W, Patrick DL, Jarvik GP, Veenstra DL.Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemp Clin Trials. 2014 Sep;39(1):1-8. doi: 10.1016/j.cct.2014.06.016. Epub 2014 Jul 3. PMID: 24997220 Free PMC Article


“Through PORPP, I established a network of peers and

mentors that I continue to learn from almost 10 years

after graduating.”

Thy Do, MPH, PhD, 2006



FACULTY GRANTS

AASTHAA BANSALPI, Comparative effectiveness of molecular response guided sequential treatment strategies in chronic myeloid leukemia, PhRMA Foundation, 2015-2016.Co-Inv (PIs: Scott Ramsey, Sean Sullivan). A Pragmatic Trial to Improve Colony Stimulating Factor Use in Cancer, PCORI, 2015-2019.Co-Inv (PI: Ken Thummel). Hormonal Regulation of Human CYP3A. NIH, 2014-2018.

ANIRBAN BASUPI Value of information methods for NHLBl trials R01HL126804, NHLBl 4/2015-3/2019

DENISE BOUDREAUCo-Principal Investigator Protocol for ER/LA Opioid Post-Marketing Requirement Studies: Observational Study #2065-1A Campbell Alliance, Ltd. Grant # SOW#1 #2065-1A (Boudreau) 7/2015-12/2016Co-Investigator/Site Principal Investigator Treatment and Outcomes in Diabetic Breast Cancer PatientsNational Cancer Institute Grant # 1R01CA188353 (Gold) 04/2015-03/2019

BETH DEVINEPI UW Site Consortium, Evidence-based Practice Center (EPC) V with Oregon Health & Science University, AHRQ, 2015 - 2019PI/Faculty Mentor, UW-Allergan Post-Doctoral Fellowship (Training Grant), Allergan Pharmaceuticals, 2012 - PI, Herb Jones Foundation. ITHS Certificate in Translational Team Science. 2015-2017

LOUIS GARRISON, JR.PI, Estimating the Burden of Illness of Giant Cell Arteritis Genentech 8/14 – 9/15PI, Pfizer Fellowship #3 Pfizer Pharmaceuticals, 7/2014-6/2016Co-Investigator, Economic analysis of an international, multi-site randomized controlled trial of ultrasound screening, RTI International 2/2014 – 12/2016

RYAN HANSENPI, A Randomized Controlled Trial of In-Home Tele-behavioral Health Care Utilizing Behavioral Activation for Depression 2015 – 2016: Geneva Foundation (Department of Defense) PI, The Army Behavioral Health Technology Office and Psychology Department at MAMC: A Tradition of Excellence in PTSD and Neuropsychological Research 2015: Geneva Foundation (Department of Defense) PI Estimating the Economic Impact of H.P. Acthar Gel in Multiple Sclerosis and Nephrotic Syndrome, 2015 – 2016, Mallinckrodt Pharmaceuticals

JERRY JARVIK Co-Investigator (Lavallee -PI) Comparing Engagement Techniques for incorporating Patient Input in Research Prioritization9/2014-9/2017 PCORICo-investigator (Flum-PI) Understanding Non-Response in Spine Fusion Surgery 7/2015-6/2016 R21AR068009 NIH

GARY LYMANCo-Investigator, PI-Ramsey Pragmatic Trial to Improve Colony Stimulating Factor Use in CancerPCORI 04/15 – 03/19 1.20 CPM

SCOTT RAMSEY PI, A Pragmatic Trial to Improve Colony Stimulating Factor Use in Cancer ” submitted to the Patient Centered Outcomes Research Institute (PCORI) for funding period 04/01/15 – 03/31/19. Funding anticipated 6/1/2015.PI, Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients, National Heart Lung and Blood Institute (NHLBI), R01 HL126589. 04/15/15 – 3/31/19.

LOTTE STEUTENCo-Investigator, PI: Pepe The Early Detection Research Network: Data Management and Coordinating CenterNational Institutes of Health 09/2015 – 08/2020

SEAN SULLIVAN Co-Investigator, PI-Scott Ramsey, MD, PhD Pragmatic Trial of Pharmacist-based Guideline Use of Colony-Stimulating Factors in Solid Organ Tumors (PCORI,) 2015-2019Principal Investigator K-12 Mentored Career Development Program in Patient-Centered Outcomes Research (AHRQ) 2014-2019

DAVID VEENSTRA Co-Investigator, Jarvik (PI) Genomic Discovery and Implementation Across a Healthcare Delivery System: Enhancing a Partnership (eMERGE) 8/15-7/16 0.60 cal. mos. Group Health Research Institute A98549Co-investigator Value of information methods for NHLBl trials R01HL126804, NHLBl 4/2015-3/2019



GIFTS


AbbVie, Inc.

Allergan

Bayer AG

Benevity

Jonathan & Christine Campbell

Josh and Amy Carlson

James T. Cross

Pete and Kathy Fullerton

Louis and Fran Garrison, Jr.

GE Foundation

GE Healthcare

Thomas Hazlet, PharmD, DrPH

PORPP would like to acknowledge our many supporters of this past

year. Our accomplishments would not have been possible without these

generous educational grants and gifts.

Mitchell and Mandy Higashi

Daniel and Rebecca Malone

Cara McDermott & Scott Gardner

Lisa Meckley and Tucker Sylvestro

Microsoft Corporation

Pacira Pharmaceuticals, Inc.

Pfizer, Inc.

Scott & Ellen Ramsey

Shelby and Steve Reed

Joshua Roth and Meghann Glavin

Julia Slejko

David E. Spackman

Andy and JoAnn Stergachis

Sean and Catrena Sullivan

Takeda Pharmaceuticals

David and Julie Veenstra

Bruce Wang, PhD

PORPP Health Technology Fund

(AbbVie, Inc., Allergan, Bayer AG,

Bristol-Myers Squibb Company,

Mindy Cheng, Genentech, Merck,

Novo Nordisk, Inc, Novartis, Pfizer,

Takeda Pharmaceuticals)


2015 PORPP RETREAT

OUR FUTURE

48


OUR FUTURE

Our Future

50 RECENT GRADUATES51 INCOMING STUDENTS

53 FACULTY & STAFF

54 ADMINISTRATION


NEW ALUMNICLASS OF 2015

PHD, MS

DOCTOR OF PHILOSOPHY DEGREES

Maria Agapova, MS, PhDDissertation: “A Decision Framework for Quantifying Benefits and Harms of Diagnostic Imaging Tests”

Chair: Beth Devine, PharmD, MBA, PhD

Caroline (Carrie) Bennette, MPH, PhDDissertation: “Prioritizing Research: The Use of Risk Prediction, Value of Information Analyses, and Portfolio Evaluation to Improve Public Investments in Cancer Clinical Trials”

Chair: David Veenstra, PharmD, PhD

Elizabeth James, PharmD, PhDDissertation: “Evaluation of a Prescription Drug Pay-for-Performance Program: Impact on Prescribing Trends, Budget and Patient Outcomes”

Chair: Tom Hazlet, Dr P.H., PhD

Kai Yeung, PharmD, PhDDissertation: “Impact of a Value Based Formulary on Health Services Utilization and Costs”

Chair: Sean Sullivan, BScPharm, MS, PhD

MASTER’S DEGREES

Katelyn Keyloun, PharmD, MSThesis: “Adherence Outcomes to Antidepressant Medication Therapy in Patients with Major Depressive Disorder”


Ryan Pistoresi, PharmDThesis: “Cost-Utility Analysis of Medications for Relaps-ing-Remitting Multiple Sclerosis from a United States Third Party Payer Perspective”

Chair: Louis Garrison, Jr., PhD

Vanessa Shih, PharmD, MSThesis: “Assessing the Burden of Worsening Self-Re-ported Vision in Older Americans”


Justin Sammy Yu, PharmD, MSThesis: “Indirect Costs and Outcomes Associated with Non-Hodgkin’s Lymphoma”

Chair: Josh Carlson, MPH, PhD

50


Sarah Baradaran, PharmD UW/ALLERGAN POST-DOCTORAL FELLOW 2015-2017

Sarah received her PharmD degree from the University of Washington School of Pharmacy in 2015. She completed a four-year clinical internship at The Everett Clinic, where she participated in P&T decision-making, conducted literature reviews and medication utilization evaluations. Sarah’s clerkships at the FDA Department of Pharmacovigilance and Evidera’s Retrospective Observational Studies team strengthened her passion for evidence generation methods in outcomes research and real-world data. Her research interests include patient reported outcomes, pharmacoepidemiology, and post-authorization observational studies. She looks forward to working with the PORPP faculty and Allergan team.

INCOMING STUDENTSWELCOME TO OUR NEW STUDENTS & FELLOWS

Horacio Duarte, MDHoracio is currently a 2nd year pediatric infectious diseases fellow at Seattle Children’s Hospital/University of Washington and is thrilled to be pursuing his research interests with PORPP. He completed his undergraduate studies at Harvard College in biological anthropology before going on to receive his M.D. at the University of Texas Medical School at Houston. During medical school, he spent a year at the NIH conducting clinical research studying cardio-metabolic complications of HIV and then went on to complete his pediatrics residency at Seattle Children’s Hospital. Horacio has had a long-standing interest in global health with a particular interest in economic evaluation of programs aimed at improving child health in resource-poor settings. He is currently studying the cost-effectiveness of HIV drug resistance testing in Kenya, and was recently awarded a Pediatric Scientist Development Program award to support his research efforts. Horacio is excited to learn from PORPP faculty and fellow students.

Elizabeth Brouwer, MPHLizzy joins PORPP from University of Washington’s Department of Global Health, where she worked for over two years as a Health Economics Analyst on Disease Control Priorities, summarizing and synthesizing economic evidence for global health interventions. Before coming to Seattle, Lizzy received her Master of Public Health in Health Economics at the University of Michigan (’13) while working with health service utilization data for tuberculosis patients in South Africa. Lizzy gained an interest in health service utilization during her time as a policy analyst in the Michigan House of Representatives, which was further strengthened by a 6-month research stint in Accra, Ghana. Lizzy is eager to hone her skills in economic evaluation and health outcomes modeling in order to continue her advocacy for efficient and effective health policy at all levels.

Nathaniel Hendrix, PharmDNathaniel earned his PharmD from the University of Washington in 2015. While a PharmD student, he completed an internship in pharmacy informatics at Virginia Mason Medical Center. There, he honed the skills that later led to his taking a position at PATH creating demand forecasts and economic models for their global health initiatives. He joins PORPP with the goal of deepening his knowledge of health economics and the methodology for determinations of value. Nathaniel’s academic interests are demand forecasting, methods for cost-effectiveness analysis, and the use of large databases and artificial intelligence in healthcare.


Catherine Lockhart, PharmD, MSCate entered the UW School of Pharmacy in 2009 as a combined PharmD/PhD student in Pharmaceutics. She earned her PharmD degree from the University of Washington in 2013, and is currently working on PhD research in the Department of Pharmaceutics to identify the pathological processes involved in the development of a rare, genetically mediated, ocular disease called Bietti’s crystalline dystrophy (BCD). She is interested in broadening her understanding of decision analytical approaches to evaluate new health technologies, but also to develop methods to inform decision makers on efficient allocation of funds to projects that are expected to have the greatest impact on advancing research. She is excited to join PORPP as a MS student to better prepare for a career as a future leader in health economics and outcomes research. Prior to graduate school, Cate trained as an electrical engineer at the University of Washington and worked as a research scientist in the Department of Radiology focusing on nuclear imaging and positron emission tomography (PET). She also holds a BFA in Theatre Arts and BS in Visual Communications from the University of Idaho.

Amy Tung, PharmD UW/ALLERGAN POST-DOCTORAL FELLOW 2015-2017

Amy received her PharmD degree from the University of Washington (UW) in 2015. Her interest in health economics and outcomes research (HEOR) grew from the desire to blend her background working in the tech industry as a market researcher with her interest in pharmaceutical outcomes and health policy. Her passion for HEOR continued to grow after taking various pharmacoeconomics and managed care electives in pharmacy school. She further developed an appreciation for the field serving as president of UW’s Academy of Managed Care Pharmacy chapter, as well as through her experience writing dossiers for pharmaceutical companies. Amy is excited for the opportunity to work with students and faculty at UW and Allergan to develop the skills necessary to become an effective health economics and outcomes researcher.

WELCOME TO OUR NEW STUDENTS Continued

Jean Malacan, PharmD, EM UW/BAYER POST-DOCTORAL FELLOW 2015-2017

Jean received his PharmD degree from the Paris Sud University in 2015, completing the same year an executive advanced master in strategy & management of health industries at the ESSEC business school. Researching in market access & pricing of orphan drugs, he received very honorable distinction for his pharmacy thesis and nomination for the annual pharmacy school award. Working a year at Ipsen, Jean built experience within the global market access and pricing team, working on endocrinology, oncology and neurology topics. He had prior training in Global R&D strategy at Sanofi. Joining the PORPP, Jean is excited to work with the excellent faculty at the University of Washington and the Bayer team, and build a deeper understanding in health economics & outcomes research, real world evidence and pricing & reimbursement strategies.

Wei-Jhih Wang, MSWei-Jhih received her MS degree in Health Services from the University of Washington in 2015, and worked with Professor Anirban Basu for her thesis about the relationship between the burden of cancer and translational research investments. In the past year, she used both a decision tree model and Markov model to evaluate cost-effectiveness for treatments of metastatic melanoma. In addition, she worked on the method for a single arm meta-analysis about liver transplantation with Drs. Susanna Nazarian and Beth Devine. Wei-Jhih also earned an MS in Biostatistics from the National Taiwan University in 2008, and worked on cancer research at a clinical trials center for several years. She is excited to join PORPP, and looks forward to enhancing her knowledge and skills in the health economics and outcomes research field.


FACULTY

Joseph Babigumira MBChB, MS, PhD, Adjunct Assistant Professor

Aasthaa Bansa, PhD, Research Assistant Professor

Anirban Basu, PhD, Professor, Stergachis Family Endowed Director, PORPP, Professor, Health Services

Denise Boudreau, PhD, Affiliate Professor

Brian Bresnahan, PhD, Adjunct Research Assistant Professor

Josh Carlson, MPH, PhD, Assistant Professor

Emily Beth Devine, PharmD, MBA, PhD, Associate Professor, Associate Director, Graduate Programs

David Flum, MD, MPH, Adjunct Professor

Louis Garrison, Jr., PhD, Professor & Interim Director

Bernardo Goulart, MD, MS, Adjunct Assistant Professor

Shelly Gray, PharmD, MS, Professor

Ryan Hansen, PharmD, PhD, Research Assistant Professor

Thomas Hazlet, PharmD, DrPH, Associate Professor

STAFF

Penny Evans Graduate Program Advisor

Laurie Gold, PhD, Research Scientist

Paul Kraegel, MSW, Program Operations Specialist

Jerry Jarvik, MD, MPH, Adjunct Professor

Larry Kessler, ScD, Adjunct Professor

Gary Lyman, MD, MPH, Co-Director, HICORE (Hutchinson Institute for Cancer Outcomes Research and Evaluation), Fred Hutchinson Cancer Research Center

Jeannine McCune, PharmD, Professor

Donald Patrick, PhD, Adjunct Professor

Scott Ramsey, MD, PhD Adjunct Professor, Director, HICORE (Hutchinson Institute for Cancer Outcomes Research and Evaluation), Fred Hutchinson Cancer Research Center

Andy Stergachis, PhD, Professor of Pharmacy and Global Health, Associate Dean, School of Pharmacy, Director, Global Medicines Program

Lotte Steuten, PhD Associate Member, HICOR (Hutchinson Institute for Cancer Outcomes Research and Evaluation), Fred Hutchinson Cancer Research Center; Associate Professor, Pharmacy

Sean Sullivan, PhD Professor, Dean of the School of Pharmacy

David Veenstra, PharmD, PhD, Professor, Associate Director, PORPP Director, Graduate Programs


PORPP ADMINISTRATION

Director Anirban Basu, PhD [email protected]

Associate Director and Director of Graduate Programs David Veenstra, PharmD, PhD [email protected]

Director of Post-PharmD Fellowship Programs Associate Director of Graduate Programs Beth Devine, PharmD, MBA, PhD [email protected]

Graduate Program Advisor Penny Evans [email protected]

Program Operations Specialist Paul Kraegel, MSW [email protected]

Research Scientist Laurie Gold, PhD [email protected]

PORPP Annual Report Team Blythe Adamson Mark Bounthavong Penny Evans Sarah Guthrie Alex Levine

Design by UW Creative Communications

PHARMACEUTICAL OUTCOMES RESEARCH & POLICY PROGR AM

Department of Pharmacy University of Washington Box 357630 Seattle, WA 98195-7630

Phone: 206-616-1383 FAX: 206-543-3835 Email: [email protected]

http://sop.washington.edu/department-of-pharmacy/pharmaceutical-outcomes-research-policy-program-porpp/

PHARMACEUTICAL OUTCOMES RESEARCH & POLICY …...May 11, 2015 · 2 pharmaceutical outcomes research...

Documents

Transcript of PHARMACEUTICAL OUTCOMES RESEARCH & POLICY …...May 11, 2015 · 2 pharmaceutical outcomes research...